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Introduction
                                      INTRODUCTION
Oral route remains the preferred route for the administration of therapeutic
agents because low cost of therapy and ease of administration leads to higher level of
patient compliance. The high level of patient compliance in taking oral dosage forms
is due to the ease of administration and handling of these forms. Although tremendous
advances have been seen in oral controlled drug delivery system in last two decades,
this system has been of limited success in the case of drugs with a poor absorption
window  throughout  the  GIT  (Gastro  Intestinal  Tract).  Drug  absorption  from  the
gastrointestinal tract is a complex procedure and is subject to many variables. It  is
widely  acknowledged  that  the  extent  of  gastro  intestinal  tract  drug  absorption  is
related to contact time with the small intestinal mucosa. Thus, small intestinal transit
time  is  an  important  parameter  for  drugs  that  are  incompletely  absorbed.  Gastro
retention helps to pro-vide better availability of new products with new therapeutic
possibilities and substantial benefits for patients.
 Controlled release drug delivery systems that retain in the stomach for a long
time  have  many  advantages  over  sustained  release  formulations.  Such  retention
systems (i.e. GRDDS) are important for the drugs that are degraded in intestine or for
drugs like antacids or certain enzymes that should act locally in the stomach. Gastric
retention may  increase  solubility  for  the  drugs which  are  poorly  soluble  in
intestine  due  to  alkaline  pH  before  they  are  emptied,  resulting  in  improved
bioavailability. These  systems  are  also  advantages  in  improving  GIT  absorption
of  a  drug  with  narrow absorption windows  as well  as  for  controlling  release  of
those  drugs which  are  having  site-specific absorption  limitations. These systems
are  useful  in  case  of  those  drugs  which  are  best  absorbed  in  stomach  for  eg.
Albuterol[5]. From  the  formulation  and  technological  point  of view,  floating  drug
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delivery   system   (FDDS)   is   considerably   easy   and   logical   approach   in
development   of   GRDFs.  Hence,  this  review  article  focuses  on  the  current
technological  development  in  FDDS  with  special  emphasis  on  the  principal
mechanism of floatation and advantages to achieve gastric retention and its potential
for oral controlled drug delivery [1].
Developments in Pharmaceutical Dosage Form Design [3]
A  drug  is  rarely  administered  to  human  being  as  a  pure  chemical
compound.   What  is  given  a  drug  product  containing the  drug.   When a drug  is
prepared in a form suitable for administration it  is called a dosage form or a drug
product or, in a modern term delivery system.
1. The first generation drug delivery systems include conventional dosage forms
such as tablets, capsules, elixirs, syrups etc.
2. The second generation drug delivery systems include repeat action, prolonged
action, and timed release dosage forms. 
3. The third generation drug delivery systems include controlled drug delivery
that refers to the precise control of the rate at which a drug dosage is released
from a delivery system.
4. The fourth  generation drug delivery systems include targetable,  modulated,
pulsatile and self regulated, or feedback controlled drug delivery systems.
5. The Fifth Generation Drug Delivery Systems include gene therapy, intended
to treat the cause of a disease rather than the symptoms.
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1.2 Conventional Release Concept [1][2] 
An ideal dosage regimen in the drug delivery of any disease is the one which
immediately attains the desired therapeutic concentration of drug in plasma (or at the
site of action) and maintains it constant for the entire duration of treatment. This is
possible through administration of a conventional dosage form in a particular dose
and at a particular frequency. The frequency of administration or the dosing interval
of  any  drug  depends  upon  its  half–life  or  mean  residence  time  (MRT)  and  its
therapeutic index. In most cases, the dosing interval is much shorter than the half–life
of the drug resulting in a number of limitations associated with such a conventional
dosage form:
1. Poor patient compliance
2. A typical peak – valley plasma concentration time profile is obtained which
makes attainment of steady state condition difficult.
3. The unavoidable fluctuations in the drug concentration.
4. The fluctuating drug levels may lead to precipitation of adverse effects. 
To  overcome  such  a  situation  concept  and  techniques  of  controlled  and
targeted delivery systems was developed.
Current Challenges in Drug Delivery [3]
The challenge of drug delivery is liberation of drug agents at the right time
in  a  safe  and  reproducible  manner,  usually  to  a  specific  target  site   To  achieve
therapeutic levels that extend over time, the initial concentration of the drug in the
body must be high, causing peaks that gradually diminish over time to an ineffective
level in this mode of delivery, the duration of the therapeutic effect depends on the
frequency of dose administration and the half-life of the drug.
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In recent years, the pharmaceutical and biotech industries have developed
more sophisticated and potent drugs. Many of these agents are proteins or DNA; the
therapeutic window (i.e.,  the range of concentrations that bracket the effective and
toxic regimes for the drug) for these drugs is often narrow; and toxicity is observed
for  concentration  spikes,  which  renders  traditional  methods  of  drug  delivery
ineffective.  A  number  of  mechanisms  can  provide  controlled  release  of  drugs
including transdermal patches, implants, inhalation systems, bioadhesive systems and
microencapsulation and now there are pioneering, commercially available products in
all of these categories.
Concept of Controlled Drug Delivery [1]
While  the  last  three  decades  have  seen  considerable  advances  in  drug
delivery  technology,  major  unmet  needs  remain.  Among  these  are  the  broad
categories of: 
1. Continuous release of therapeutic agents over extended time periods and in
accordance with a pre-determined temporal profile 
2. Local delivery of agents at pre-determined rates to local sites, such as solid
tumors, to overcome systemic drug toxicity and improve anti-tumor activity
and 
3. Improved  ease  of  administration,  which would increase  patient  compliance
while  minimizing  the  need  for  intervention  by  health  care  personnel  and
decreasing the length of hospital stays.  Success in addressing some or all of
these  challenges  potentially  would  lead  to  improvements  in  efficacy  and
patient compliance as well as minimization of side effects.
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Despite the several advantages associated with oral controlled drug delivery
systems, there are so many disadvantages, which are: 
 Basic assumption is drug should absorb throughout GI tract.
 Limited gastric residence time which ranges from few minutes to 12 hours
which  lead  to  unpredictable  bioavailability  and  time  to  achieve  maximum
plasma level.
 Intersubject variability.
 Relatively poor in vitro / in vivo correlation.
 Sometimes unpredictable and often reduced bioavailability.
 Possible dose dumping
 Narrow absorption window in GI tract e.g. Levodopa, Riboflavin
 Primarily absorbed from stomach and upper part  of  GI tract  e.g.  Atenolol,
Cinnarazine, Chlordiazepoxide, Calcium Supplement
 Act locally in stomach e.g. Misoprostol, Antacids
 Drug that degrade in colon e.g. Ranitidine HCL, Metronidazole
 Drug that disturb normal colonic bacterial  flora e.g.  Amoxicillin trihydrate,
Cefuroxime axetil, Clindamycin etc.
Thus  the  drug  candidates  having  ‘absorption  window’  in  a  particular
region of GI tract are difficult to be designed as oral Controlled release drug delivery
system (CRDDS).  This is because only the drug released in the region preceding the
‘window’  and  vicinity  of  ‘absorption  window’  is  available  for  absorption.  Drug
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released from the CRDDS after the ‘absorption window’ has been crossed goes waste
with no or negligible absorption occurring. This phenomenon drastically decreases the
time  available  for  drug  absorption,  after  release  of  drug  from  CRDDS,  thus
jeopardizing the success of delivery system.
The CRDDS possessing the ability of being retained in the stomach are
called  gastro  retentive  drug  delivery  systems  (GRDDS)  and  they  can  help  in
optimizing  the  oral  controlled  delivery  of  drug  having  ‘absorption  window’  by
continuously releasing drug prior to absorption window, for prolonged period of time
thus ensuring optimal bioavailability.
Need for GRDDS, (a) Conventional drug delivery system, (b) GRDDS
It  is  evident  from  the  recent  scientific  and  patent  literature  that  an
increased  interest  in  NDDS  that  are  retained  in  the  stomach  for  prolonged  and
predictable period of time exists today in academic and industrial research groups.
The most feasible approach for that is GRDDS.
Gastro retentive technologies [4]
A number of techniques have been used to increase the gastric residence
time (GRT) of dosage forms by employing a variety of concepts which are:
Floating systems [5]
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Floating systems are low-density systems that have sufficient buoyancy to
float  over  the gastric  contents  and remain  in the stomach for  a  prolonged  period.
While the system floats over the gastric contents, the drug is released slowly at the
desired rate, which results in increased GRT and reduces fluctuation in plasma drug
concentration. Floating systems can be classified as effervescent and non-effervescent
stems.
Classification of gastro retentive drug delivery systems.
Mechanism of GRDDS
Bio/mucoadhesive systems [6]
Department of Pharmaceutics JKKMMRF College of pharmacy7
Chapter  1                                                                                                    
Introduction
Bio/mucoadhesive systems bind to the gastric epithelial cell surface, or mucin,
and extend the GRT by increasing the intimacy and duration of contact between the dosage
form and the biological  membraneThese can be subdivided into three broad categories:
hydration-mediated adhesion, bonding-mediated adhesion, and receptor-mediated adhesion. 
Swelling systems [6][7][8]
After  being  swallowed, these dosage forms swell  to a size that prevents
their  passage  through the  pylorus  As a  result,  the dosage  form is  retained  in  the
stomach for a long period of time. 
Relationship between the degree of cross-linking of the polymeric chains and the
swelling 
An  optimum  amount  of  cross-linking  is  required  to  maintain  a  balance
between swelling and dissolution.
High-density systems [6][8]
These systems, which have a density of ~3 g/cm3, are retained in the rugae
of the stomach and are capable of withstanding its peristaltic movements. Above a
threshold density of 2.4–2.8 g/cm3, such systems can be retained in the lower part
of the stomach. 
Gastro retentive dosage forms overcome the limitation of conventional oral
controlled drug delivery system by:
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 Prolonging the GRT by retaining dosage form in stomach and upper part of
GI tract.
 Give sufficient time for drug to release from dosage form.
 Give sufficient time for drug to be absorbed through GI tract.
 Protecting the drug to degrade in colon.
 Protecting  the  degradation  of  normal  GI  flora  by  restricting  the  dosage
form in stomach and upper part of GI tract.
From the formulation and technological point of view, the floating drug
delivery system (FDDS) is considerably easy and logical approach in development
of  gastroretentive  dosage  forms.  Hence  for  the  present  study,  formulation  of
GRDDS is prepared as floating drug delivery system.
FLOATING SYSTEMS 
Floating drug delivery have the property of retaining the dosage units in the
stomach for prolonged period of time and are useful for drugs acting locally in the
gastro intestinal tract (GIT), drugs which are poorly soluble and unstable in intestinal
fluids.  Recently various efforts are being made to design floating systems such as
Floating  Drug  delivery  systems  (FDDS),  Swelling  and  Expanding  Systems,  Bio
adhesive systems, Modified shape systems, High density systems etc. These systems
are advantageous in improving GIT absorption of drug with controlled release due to
specific site absorption limitations. The main objective of developing these systems is
to increase the safety of a product to extend its duration of action and decrease side
effects  of  drugs.  These systems have more  flexibility in  dosage  form design  than
conventional  dosage  form.  Several  approaches  have  recently  been  developed  to
Department of Pharmaceutics JKKMMRF College of pharmacy9
Chapter  1                                                                                                    
Introduction
extend  gastrointestinal  transit  time by prolonging  residence  time of  drug  delivery
system in the GIT.  
Basic  of  this  drug  delivery  system is  to  optimize  biopharmaceutic,
pharmacokinetic  and  pharmacodynamic  properties  of  drugs  in  such  a  way that  to
reduce dosing frequency to an extent that once daily dose sufficient for therapeutic
management  through  uniform plasma concentration  providing maximum utility  of
drug through reduction in local  and systematic  side effects  and cure or controlled
condition  in  shortest  possible  time by smallest  quantity  of  drug  to  assure  greater
patient compliance.
 Gastro retentive systems can remain in the gastric region for several hours
and hence significantly prolong the gastric residence time of drugs. Prolonged gastric
retention improves bioavailability,  reduces drug waste,  and improves solubility for
drugs that are less soluble in a high pH environment. It has applications also for local
drug delivery to the stomach and proximal small intestines. Gastro retention helps to
provide  better  availability  of  new products  with  new therapeutic  possibilities  and
substantial benefits for patients.
The controlled gastric retention of solid dosage forms may be achieved by the
mechanisms of  mucoadhesion,  flotation,  sedimentation,  expansion,  modified shape
systems, or by the simultaneous administration of pharmacological agents that delay
gastric emptying. Based on these approaches, classification of floating drug delivery
systems (FDDS) has been described in detail. In vivo/in vitro evaluation of FDDS has
been discussed by scientists to assess the efficiency and application of such systems.
Several recent examples have been reported showing the efficiency of such systems
for drugs with bioavailability problems.
Department of Pharmaceutics JKKMMRF College of pharmacy10
Chapter  1                                                                                                    
Introduction
FACTORS AFFECTING GASTRIC RETENTION
Gastric residence time of an oral dosage form is affected by several factors. To
pass through the pyloric valve into the small intestine the particle size should be in the
range of 1 to 2 mm. The pH of the stomach in fasting state is ~1.5 to 2.0 and in fed
state is 2.0 to 6.0. A large volume of water administered with an oral dosage form
raises the pH of stomach contents to 6.0 to 9.0. Stomach doesn’t get time to produce
sufficient acid when the liquid empties the stomach; hence generally basic drugs have
a better chance of dissolving in fed state than in a fasting state.
The rate of gastric emptying depends mainly on viscosity, volume, and caloric
content of meals. Nutritive density of meals helps determine gastric emptying time. It
does not make any difference whether meal has high protein,  fat,  or carbohydrate
content as long as the caloric content is the same. However, increase in acidity and
caloric value slows down gastric emptying time.
 Biological factors such as age, body mass index (BMI), gender, posture, and
diseased states (diabetes, Chron’s disease) influence gastric emptying. In the case of
elderly persons,  gastric  emptying is  slowed down.  Generally  females  have slower
gastric  emptying  rates  than  males.  Stress  increases  gastric  emptying  rates  while
depression slows it down.
The  resting  volume  of  the  stomach  is  25  to  50  ml.  Volume  of  liquids
administered affects the gastric emptying time. When volume is large, the emptying is
faster.  Fluids  taken  in  body  temperature  leave  the  stomach  faster  than  colder  or
warmer fluids. Studies have revealed that gastric emptying of a dosage form   the fed
state can also be influenced by its size. Small-size tablets leave the stomach during the
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digestive  phase  while  the  large-size  tablets  are  emptied  during  the  housekeeping
waves.
Timmermans & Andre25 studied the effect of size of floating and nonfloating
dosage  forms on gastric  emptying  and concluded  that  the floating units  remained
buoyant  on  gastric  fluids.  These  are  less  likely  to  be  expelled  from the  stomach
compared with the non floating units, which lie in the antrum region and are propelled
by the peristaltic waves.
It  has  been  demonstrated  using  radiolabeled  technique  that  there  was  a
difference  between  gastric  emptying  times  of  a  liquid,  digestible  solid,  and
indigestible solid. It was suggested that the emptying of large (>1 mm) indigestible
objects  from  stomach  was  dependent  upon  interdigestive  migrating  myoelectric
complex. When liquid and digestible solids are present at stomach, it contracts 3 to 4
times per minute leading to the movement of the contents through partially opened
pylorus.  Indigestible solids larger  than the pyloric  opening are propelled back and
several phases of myoelectric activity take place when the pyloric opening increases
in size during the housekeeping wave and allows the sweeping of the indigestible
solids. Studies have shown that the gastric residence time {GRT} can be significantly
increased under the fed conditions since the MMC is delayed.
Several  formulation parameters  can  affect  the  gastric  residence  time.  More
reliable gastric emptying patterns are observed for multi particulate formulations as
compared with single unit formulations, which suffer from “all or none concept.” As
the  units  of  multi  particulate  systems  are  distributed  freely  throughout  the
gastrointestinal tract, their transport is affected to a lesser extent by the transit time of
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food compared with single unit formulation. Size and shape of dosage unit also affect
the gastric emptying.
 Floating units away from the gastro-duodenal junction were protected from
the peristaltic waves during digestive phase while the non floating forms stayed close
to the pylorus and were subjected to propelling and retropelling waves of the digestive
phase.  It  was also observed that of the floating and non floating units, the floating
units were had a longer gastric residence time for small and medium units while no
significant difference was seen between the 2 types of large unit dosage forms.
Intragastric residence positions of floating and nonfloating units.
When  subjects  were  kept  in  the  supine  position  it  was  observed  that  the
floating  forms  could  only  prolong  their  stay  because  of  their  size;  otherwise  the
buoyancy remained no longer an advantage for gastric retention.
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A comparison  was made to  study the affect  of  fed  and  non-fed  stages  on
gastric emptying. For this study all subjects remaining in an upright position were
given a light breakfast and another similar group was fed with a succession of meals
given at normal time intervals.
It  was  concluded  that  as  meals  were  given  at  the time when the  previous
digestive phase had not completed, the floating form buoyant in the stomach could
retain its position for another digestive phase as it was carried by the peristaltic waves
in the upper part of the stomach.
TYPES OF FLOATING DRUG DELIVERY SYSTEMS (FDDS) [11][12]
Based on the mechanism of buoyancy,  two distinctly different  technologies
have been utilized in development of FDDS, which are:
A. Effervescent System, and
B. Non- Effervescent System.
A.  EFFERVESCENT SYSTEM: -
Effervescent  systems  include  use  of  gas  generating agents,  carbonates  (eg.
sodium bicarbonate) and other organic acid (e.g. citric acid and tartaric acid) present
in the formulation to produce carbon dioxide (CO2) gas, thus reducing the density of
the system and making it float on the gastric fluid. An alternative is the incorporation
of matrix containing portion of liquid, which produce gas  that  evaporates  at  body
temperature.
These effervescent systems further classified into two types.
I      Gas Generating systems 
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II     Volatile Liquid/Vacuum Containing Systems
I. Gas – Generating Systems:
1. Intra Gastric Single Layer Floating Tablets or Hydrodynamically Balanced
System (HBS):
These are formulated by intimately mixing the CO2 generating agents and the
drug within the matrix tablet.These have a bulk density lower than gastric fluids and
therefore remain floating in the stomach unflattering the gastric emptying rate for a
prolonged  period.  The drug is  slowly released  at  a  desired  rate  from the floating
system  and  after  the  complete  release  the  residual  system  is  expelled  from  the
stomach. This leads to an increase in the GRT and a better control over fluctuations in
plasma drug concentration.
2.  Intra Gastric Bilayer Floating Tablets:
      These are also compressed tablet as shown in Fig 6 and containing two layer i.e., 
         Immediate release layer and  Sustained release layer.  
Figure 2. Intra gastric bilayer floating tablet.
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3. Multiple Unit type floating pills:
These  systems  consist  of  sustained  release  pills  as  ‘seeds’  surrounded  by
double layers. The inner layer consists of effervescent agents while the outer layer is
of swellable membrane layer. When the system is immersed in dissolution medium at
body temp, it sinks at once and then forms swollen pills like balloons, which float as
they have lower density. This lower density is due to generation and entrapment of
CO2 within the system. 
 II. Volatile Liquid / Vacuum Containing Systems:
1. Intragastric Floating Gastrointestinal Drug Delivery System:[13]
These  systems  can  be  made  to  float  in  the  stomach  because  of  floatation
chamber, which may be a vacuum or filled with air or a harmless gas,  while drug
reservoir is encapsulated inside a micro porous compartment.          
2. Inflatable Gastrointestinal Delivery Systems:
In these systems an inflatable chamber is incorporated, which contains liquid
ether that gasifies at body temperature to cause the chamber to inflate in the stomach.
These systems are fabricated by loading the inflatable chamber with a drug reservoir,
which can be a drug, impregnated polymeric matrix, then encapsulated in a gelatin
capsule. After oral administration, the capsule dissolves to release the drug reservoir
together with the inflatable chamber.  The inflatable chamber automatically inflates
and retains the drug reservoir compartment in the stomach. The drug is continuously
released from the reservoir into the gastric fluid.
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3. Intragastric Osmotically Controlled Drug Delivery System:  
It is comprised of an osmotic pressure controlled drug delivery device and an
inflatable floating support in a biodegradable capsule.  In  the stomach,  the capsule
quickly disintegrates to release the intragastric osmotically controlled drug delivery
device. The inflatable support inside forms a deformable hollow polymeric bag that
contains a liquid that gasifies at body temperature to inflate the bag.  The osmotic
pressure controlled drug delivery device consists of two components; drug reservoir
compartment and an osmotically active compartment. 
The  drug  reservoir  compartment  is  enclosed  by  a  pressure  responsive
collapsible bag, which is impermeable to vapor and liquid and has a drug delivery
orifice. The osmotically active compartment contains an osmotically active salt and is
enclosed within a semipermeable housing. In the stomach, the water in the GI fluid is
continuously absorbed through the semipermeable membrane into osmotically active
compartment  to  dissolve  the  osmotically  active  salt.  An  osmotic  pressure  is  thus
created  which  acts  on  the  collapsible  bag  and  in  turn  forces  the  drug  reservoir
compartment to reduce its  volume and activate the drug reservoir compartment  to
reduce its volume and activate the drug release of a drug solution formulation through
the delivery orifice. 
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              Fig 4. Intragastric osmotically controlled drug delivery system.
B. NON EFFERVESCENT SYSTEMS:
The Non-effervescent FDDS based on mechanism of swelling of polymer or
bioadhesion to mucosal layer in GI tract. The most commonly used excipients in non-
effervescent FDDS are gel forming or highly swellable cellulose type hydrocolloids,
polysaccharides  and  matrix  forming  material  such  as  polycarbonate,  polyacrylate,
polymethacrylate, polystyrene as well as bioadhesive polymer such as Chitosan and
Carbopol. The various types of this system are as:
1. Single Layer Floating Tablets: [14] [15].
They  are  formulated  by  intimate  mixing  of  drug  with  a  gel-forming
hydrocolloid, which swells in contact with gastric fluid and maintain bulk density of
less than unity.  The air trapped by the swollen polymer confers buoyancy to these
dosage forms. 
2. Bilayer Floating Tablets:
A bilayer tablet contain two layer one immediate release layer which release
initial  dose  from system while  the another  sustained  release  layer  absorbs  gastric
fluid, forming an impermeable colloidal gel barrier on its surface, and maintain a bulk
density of less than unity and thereby it remains buoyant in the stomach.   
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3.  Alginate Beads: [16]
Multi unit floating dosage forms were developed from freeze-dried calcium
alginate.  Spherical  beads  of  approximately  2.5  mm diameter  can  be  prepared  by
dropping  a  sodium  alginate  solution  into  aqueous  solution  of  calcium  chloride,
causing  precipitation  of  calcium  alginate  leading  to  formation  of  porous  system,
which can maintain a floating force for over 12 hours. When compared with solid
beads, which gave a short residence, time of 1 hour, and these floating beads gave a
prolonged residence time of more than 5.5 hour.
4. Hollow Microspheres:
Hollow microspheres (microballoons), loaded with drug in their outer polymer
shells  were  prepared  by a  novel  emulsion-solvent  diffusion  method.  The  ethanol:
dichloromethane solution of the drug and an enteric acrylic polymer was poured into
an agitated aqueous solution of PVA that was thermally controlled at 400C. The gas
phase  generated  in  dispersed  polymer  droplet  by  evaporation  of  dichloromethane
formed an internal cavity in microspheres of polymer with drug. The microballoons
floated continuously over the surface of acidic dissolution media containing surfactant
for more than 12 hours in vitro.
Advantages of Floating Delivery System.[17]. 
 Enhanced bioavailability enhanced first pass biotransformation. 
 Sustained drug delivery/reduced frequency of dosing. 
 Targeted therapy for local ailments in the upper GIT. 
 Reduced fluctuation of drug concentration. 
 Improved receptor activation selectivity. 
 Reduced counter-activity of the body. 
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 Extended time over critical (effective) concentration. 
 Minimized adverse activity at the colon. 
 Site specific drug delivery 1. 
Disadvantages of floating drug delivery system [17]. 
 Floating system is not feasible for those drugs that have solubility or stability
problem in GI tract. 
 These systems require a high level of fluid in the stomach for drug delivery to
float and work efficiently. 
 The  drugs  that  are  significantly  absorbed  throughout  gastrointestinal  tract,
which undergo significant first pass metabolism, are only desirable candidate. 
 Some drugs present in the floating system causes irritation to gastric mucosa. 
Application  of  Floating  Drug  Delivery  Systems:  Floating  drug  delivery  offers
several  applications  for  drugs  having  poor  bioavailability  because  of  the  narrow
absorption window in the upper part of the gastrointestinal tract. It retains the dosage
form  at  the  site  of  absorption  and  thus  enhances  the  bioavailability.  These  are
summarized as follows. 
1.  Sustained  Drug  Delivery:  HBS  systems  can  remain  in  the  stomach  for  long
periods and hence can release the drug over a prolonged period of time. The problem
of short gastric residence time encountered with an oral CK formulation hence can be
overcome with these systems. These systems have a bulk density of <1 as a result of
which they can float on the gastric contents. These systems are relatively large in size
and passing from the pyloric  opening is  prohibited.  Eg:  Sustained release floating
capsules of nicardipine hydrochloride were developed and were evaluated in vivo.
The  formulation  compared  with  commercially  available  MICARD  capsules  using
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rabbits. Plasma concentration time curves showed a longer duration for administration
(16 hours) in the sustained release floating capsules as compared with conventional
MICARD capsules (8 hours) [26].
 2.  Site-Specific  Drug Delivery:  These systems  are  particularly  advantageous for
drugs that are specifically absorbed from stomach or the proximal part of the small
intestine, e.g.:  Riboflavin and furosemide.  E.g.:-  Furosemide is  primarily absorbed
from the stomach followed by the duodenum. It has been reported that a monolithic
floating dosage form with prolonged gastric residence time was developed and the
bioavailability  was  increased.  AUC  obtained  with  the  floating  tablets  was
approximately 1.8 times those of conventional furosemide tablets27. 
3. Absorption Enhancement:  Drugs that have poor bioavailability because of site-
specific  absorption  from  the  upper  part  of  the  gastrointestinal  tract  are  potential
candidates to be formulated as floating drug delivery systems, thereby maximizing
their absorption. Eg: A significantly increase in the bioavailability of floating dosage
forms(42.9%) could be achieved as compared with commercially available LASIX
tablets (33.4%) and enteric coated LASIX-long product (29.5%).
1.7 Factors Controlling Gastric Retention Time of Dosage Form: 
The  gastric  retention  time (GRT)  of  dosage  form is  controlled  by  several
factors, which affect their efficacy as a Gastro retentive system. 
• Density – GRT is a function of dosage form buoyancy that is dependent on the
density.
• Size – Dosage form units with a diameter of more than 9.5 mm are reported to
have an increased GRT.
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• Shape of dosage form – Tetrahedron and ring-shaped devices with a flexural
modulus of 48 and 22.5 kilo pounds per square inch (KSI) are reported to have
better GRT. 90% to 100% retention at 24 hours compared with other shapes.
• Single or multiple unit formulation – Multiple unit formulations show a more
predictable release profile and insignificant impairing of performance due to
failure of units, allow co-administration of units with different release profiles
or containing incompatible substances and permit a larger  margin of safety
against dosage form failure compared with single unit dosage forms.
• Fed or unfed state – Under fasting conditions, the GI motility is characterized
by  periods  of  strong  motor  activity  or  the  migrating  myoelectric  complex
(MMC)  that  occurs  every  1.5  to  2  hours.  The  MMC  sweeps  undigested
material  from  the  stomach  and,  if  the  timing  of  administration  of  the
formulation coincides  with that  of  the MMC, the GRT of  the unit  can  be
expected to be very short. However,  in the fed state,  MMC is delayed and
GRT is considerably longer. 
• Nature  of  meal  –  Feeding  of  indigestible  polymers  or  fatty  acid  salts  can
change the motility pattern of the stomach to a fed state, thus decreasing the
gastric emptying rate and prolonging drug release.
•  Caloric content – GRT can be increased by four to 10 hours with a meal that
is high in proteins and fats. 
• Frequency  of  feed  –  The  GRT  can  increase  by  over  400  minutes  when
successive  meals  are  given  compared  with  a  single  meal  due  to  the  low
frequency of MMC.
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• Gender – Mean ambulatory GRT in males (3.4±0.6 hours) is less compared
with  their  age  and  race-matched  female  counterparts  (4.6±1.2  hours),
regardless of the weight, height and body surface.
• Age – Elderly people, especially those over 70, have a significantly longer
GRT.
• Posture – GRT can vary between supine and upright ambulatory states of the
patient.
• Concomitant  drug  administration  –  Anticholinergics  like  Atropine  and
Propantheline,  opiates  like  Codeine  and  prokinetic  agents  like
Metoclopramide and Cisapride.
• Biological factors – Diabetes and Crohn’s disease.
In  general,  the drugs best  suited for  incorporation into an external  product
have the following properties
Definition of Angina pectoris and types of Angina [9]:
Angina pectoris is a symptom of an underlying heart condition. It means that
the  heart  is  not  getting  enough  blood  and  as  a  result,  not  enough  oxygen.  This
decrease of oxygen being delivered to the muscle of the heart happens if one or more
coronary arteries are narrowed or blocked, a condition called atherosclerosis.
Blood enters  the heart  through two blood vessels.  These are known as  the
coronary  arteries  and  they  supply  the  heart  muscle  with  the  blood,  oxygen  and
nutrients  it  needs to  keep beating.  Normally,  the coronary arteries  deliver  enough
blood so that the heart muscle gets the amount of oxygen it needs to work properly.
However, in coronary heart disease these arteries become narrowed which reduces the
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amount of blood that can pass through arteries causes  blood can't  get  to the heart
muscle fast enough and the heart complains with pain. This pain is known as angina.
It is more likely to occur during exertion (for example, walking or climbing stairs)
when the heart muscle needs more blood and oxygen as it works harder.
An episode  of  angina  is  not  a  heart  attack.  Angina  is  due  to  a  temporary
reduction in the flow of blood to part of the heart muscle and does not damage the
heart itself. A heart attack occurs when the blood supply to part of the heart is cut off
and results in permanent damage to the heart muscle. However, angina does indicate
an increased risk of a heart attack. Angina is common. It is more common in men than
women and the likelihood of it occurring increases with age.
1.1.2. Types of Angina
Anginas are categorized in to several ways:
• Stable Angina:
This is the most common type of angina occurring due to physical exertion
such as walking up stairs,  running to catch a bus,  mental  or emotional stress  and
physical  exercise  that  causes  strain  with the pain being predictable.  Stable angina
follows a regular pattern and the pain/discomfort subsides on taking rest and slowing
down, but returns with the resumption of activity.
• Unstable Angina:
 With unstable angina, chest pain is unexpected and occurs with little physical
effort or when the patient is at rest and the pain may be severe, prolonged and more
frequent  as  compared  to  stable  angina.  Sometimes,  stable  angina  can  progress  to
unstable angina or an unstable angina can also develop from inflammation, infection,
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abnormal constriction of the artery or partial blockade of the artery due to a blood
clot. Unstable angina does not follow a regular pattern and can prove to be fatal if
there is not immediate medical attention.
• Variant Angina or Prinzmetal’s Angina: 
It often occurs while someone is resting (usually between midnight and 8:00 in
the  morning),  and  it  has  no  predictable  pattern—that  is,  it  is  not  brought  on  by
exercise or emotion. This kind of angina may cause severe pain, and is usually the
result of a spasm in a coronary artery.  Most people who have variant angina have
severe  atherosclerosis  (hardening of  the arteries),  and the spasm is  most  likely to
occur near a buildup of fatty plaque in an artery.
• Microvascular Angina:
 In this type, chest pain occurs but without any blockage in a coronary artery.
The pain is due to improper functioning of the tiny arteries supplying blood to the
heart. This condition is referred to as Syndrome X.
• Atypical Angina: 
 Typical  symptoms of  angina  may not  be  experienced  in  this  type  and  the
patient may experience a mild chest discomfort, shortness of breath, fatigue, nausea,
back  or  neck  pain,  or  burning  indigestion.  Women are  more  prone  to  experience
symptoms of atypical angina.
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1.1.3. Classes of Drugs Used to Treat Angina.[10]
Classes of drugs used in the treatment of angina and myocardial infarction are
given below.
1.   Vasodilators (dilate arteries and veins)
                          - Calcium-channel blockers (Verapamil)
                          - Nitro dilators (Nitroglycerin)
1. Cardioinhibitory drugs (reduce heart rate and contractility)
                 -  Beta-blockers(Metoprolol)
                 -  Calcium-channel blockers
2. Blocker of late sodium currents (FDA approved 1/06)
                              -  Ranolazine
3. Anti-thrombotic drugs (prevent thrombus formation)
                  -  anticoagulants(Warfarin)
                  -  anti-platelet drugs(Aspirin)
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LITERATURE REVIEW
1. M Vanaja  kumari  et  al  (2012) prepared  and characterized  the Sustained release
matrix tablets of Ranolazine using Kollidon SR. Three different strengths i.e. 375mg,
500mg and 750mg of Ranolazine SR tablets were prepared by direct  compression
method and by using common blend. The influence of compression force was studied
on the dissolution release profile of Ranolazine SR tablets. In vitro release studies
were performed for all the formulations using USP type II apparatus (paddle method)
in 900 ml of 0.1N hydrochloric acid at 50 rpm for 24 hours and analyzed by UV
spectrophotometer  at  272nm.  Further,  in-vitro  release  pattern  of  drug  from  the
optimized formulation was compared with innovator formulation and it was found to
be super imposable with the Innovator product RANEXA based on dissimilarity and
similarity factors.
2. Anilkumar J. Shinde et al (2010) formulated an oral floating tablet of cephalexin
(CEF) using the hydrophilic polymer hydroxy propyl methyl cellulose (HPMC), gas
generating agent sodium bicarbonate and citric acid. The granules were prepared by
wet  granulation  method and  evaluated  for  their  granules  properties.  Tablets  were
compressed  by  KBr  press  and  evaluated  with  different  parameters  like  diameter,
thickness, average weight, hardness, friability, drug content, in vitro buoyancy study,
swelling characteristics, scanning electron microscopy, kinetic release data.
3. M.  Ranga  Priya  et  al  (2011)  developed  sustained-release  drug  delivery  system
containing Ranolazine (an anti-anginal  drug) with different  ratios of pH dependent
polymer;  Eudragit  L100-55  was  designed  by  wet  granulation  method.  The
physicochemical  compatibility  of  the  drug  and  polymers  were  studied  by  FTIR
spectrophotometer  and  found  to  be  compatible.  The  promising  formulation  with
concentration  of  Eudragit  L100-55  polymer  12.5%  showed  better  release  of
99.78±0.99% after 24 hours. It showed Zero-order release with linearity (r=0.9447 to
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0.9895).  The similarity factor (f2  values)  was used for the comparison of  in vitro
release  study  of  the  best  formulation  of  SR tablets  and  marketed  ER product  of
Ranolazine. 
4. Jagdish Bidada et al (2011) incorporated Ranolazine into monolithic matrices whose
excipients  were  mixtures  at  different  ratios  of  a  acrylic  resin  (Carbopol  971  P)
hydrophilic & pHdependent nature and an ethylcellulose (Ethocel N20/N50), water-
insoluble and pH-independent polymers. Technological characterization (drug particle
morphology, mean weight, diameter, thickness, hardness and friability of tablets) was
carried out and in vitro drug release behavior was measured using the USP Type II
(Paddle) apparatus. The effect of varying the Carbopol–Ethocel ratio, as well as the
drug–polymeric  matrix  ratio,  was  evaluated  by  simple  factorial  design  using  two
independent factors. The results showed the suitability of Carbopol–Ethocel mixtures
as  matrix-forming  material  for  Ranolazine  Extended  release  formulations.
Combination of the swelling properties of Carbopol 971 P with the plastic properties
of the more hydrophobic Ethocel N20/N50 allowed suitable modulation of Ranolazine
release. 
5. A. K. Srivastava et.al. (2005) developed floating matrix tablets of atenolol to prolong
gastric residence time and increase drug bioavailability. The tablets were prepared by
direct compression technique, using polymers such as hydroxypropyl methylcellulose
(K15M,  K4M),  guar  gum  and  sodium  carboxymethylcellulose,  alone  or  in
combination.
6. Aisha Khanum  et.al. (2009) developed bilayer tablets of propanolol hydrochloride
the result of these was bilayer tablet it is possible to have a fast releasing layer and
sustaining layer so as to have a zero order of water soluble drugs like propanolol can
be achieved.
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7. Dave  B.  S.  et.al.  (2004) developed  a  floating  drug  delivery  system  of  ranitidine
hydrochloride.  Guar  gum,  xanthan  gum  and  hydroxypropyl  methylcellulose  were
evaluated for gel-forming properties. The effects of citric acid and stearic acid on drug
release profile and floating properties were investigated by using full factorial design.
The results indicated that a low amount of citric acid and a high amount of stearic acid
favors  sustained  release  of  ranitidine  hydrochloride  from  a  gastro  retentive
formulation.  No  significant  difference  was  observed  between  the  desired  release
profile and optimized batches. These studies indicate that the proper balance between
a release rate enhancer and a release rate retardant can produce a drug dissolution
profile similar to a theoretical dissolution profile.
8. Dhumal R.S. et.al. (2006) developed bilayer floating tablets of cefuroxime axetil for
bimodal release using  hydroxypropyl  cellulose,  hydroxypropyl  methylcellulose and
tulsion T-339 to providing sustained release upto 24 h.  The result showed that oral
solid dosage form based on bilayer  floating drug delivery is promising to achieve
bimodal drug release.  After  an immediate drug release  from first  layer,  controlled
release  can  be  achieved  from  second  layer  in  an  area  that  could  maximize  drug
reaching its absorption site.
9. Jagadeesh  Nadigoti  et.al.  (2009) review  the  floating  drug  delivery  system  and
concluded that the growing impact of GIT physiology on drug delivery and increasing
sophistication of drug delivery technology will ensure development of an increasing
number  of  GRDDs  to  optimize  drug  delivery  of  molecules  exhibiting  regional
variability in drug absorption.
10. Narendra  C.  et.al. (2006) developed  an  optimized  gastric  floating  drug  delivery
system containing metoprolol tartarate as a model drug by the optimization technique.
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They studied effect of hydroxypropyl methylcellulose (K4M and K100M) on release
and  floating  characteristics  of  metoprolol  tartarate  tablets.  The  effect  of  different
viscosity  grades  of  hydroxypropyl  methylcellulose  (K4M  and  K100M)  was
nonsignificant.  Fickian  release  transport  was  confirmed  as  the  release  mechanism
from the optimized formulation.
11. Nitin G.  Sampat  et.al. (2009) developed once daily baclofen sustained release or
gastro-retentive  systems  which  are  acceptable  alternatives  to  thrice  daily  baclofen
immediate release at the same daily dosage in patients. The result showed that once-
daily  baclofen  sustained  are  efficacious,  convenient,  and  better  alternatives  to
baclofen immediate  release in  patients  with neurogenic  spasticity.  Considering the
entire parameters evaluated baclofen sustained release is superior in safety to baclofen
immediate release.
12. Ozdemir  et.al. (2000) developed floating bilayer tablets with controlled release for
furosemide. This study was designed to enhance the bioavailability of furosemide by
prolonging its duration in the stomach via the floating dosage forms with controlled
release. All formulations were prepared as two-layer tablets. The first layer provided
floating and contained the mixture of sodium bicarbonate and citric acid to form air
bubbles and HPMC K4M as a matrix material to retain the air bubbles. The second
layer (release layer) provided controlled release of active material. It contained active
material and HPMC K100M as hydrophilic matrix material.
13. Prajapati S. T.  et.al. (2008) developed an optimized gastric floating drug delivery
system containing domperidone as a model drug. Box-Behnken design was employed
in formulating the GFDDS with three polymers: hydroxypropyl methylcellulose K4M
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(HPMC K4M), Carbopol 934P and sodium alginate. The study showed that HPMC
K4M, Carbopol 934P and SA significantly affect TFT of the formulated GFDDS.37
14. Manoj  N.  Gambhire  et  al  (2008)  developed  floating  matrix  tablets  of  DTZ  to
prolong  gastric  residence  time  and  increase  its  bioavailability..  The  tablets  were
prepared by direct compression technique, using polymers such as hydroxyl propyl
methylcellulose  (HPMC,  Methocel  K100M  CR),  Compritol  888  ATO,  Sodium
bicarbonate.. A 32 factorial design was applied to systematically optimize the drug
release profile.The amounts of Methocel K100M CR (X1) and Compritol 888 ATO
(X2) were selected as independent variables.  The time required for 50% (t50) and
85%  (t85)  drug  dissolution  were  selected  as  dependent  variables.  The  results  of
factorial design indicated that a high level of both Methocel K100M CR (X1) and
Compritol 888 ATO (X2) favors the preparation of floating controlled release of DTZ
tablets. 
15. Shailesh T. Prajapati et al (2005)  studied to develop an optimized gastric floating
drug delivery system (GFDDS) containing domperidone. Box-Behnken design was
employed  in  formulating  the  GFDDS  with  three  polymers:  hydroxypropyl
methylcellulose K4M (HPMC K4M) (X1), Carbopol 934P (X2) and sodium alginate
(X3), as independent variables.  Floating lag time (FLT),  total floating time (TFT),
time  required  to  release  50%  of  the  drug  (t50)  and  diffusion  exponent  (n)  were
selected as dependent variables, dissolution data obtained was fitted to the power law
and floating profiles were analyzed. HPMC loading was found to be significant for
floating propertiesand desired release.
16. Shawky  Tous S.  et  al  (2003) developed  Nitrofurantoin  floating  matrix  tablets,
Hydroxypropyl methylcellulose (HPMC) of different viscosity grades together with a
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gas  generating  agent  (sodium  bicarbonate)  and  other  optional  additives  were
examined to optimize the floating characters of the prepared tablets. The in vitro study
of the floating behavior  in  simulated  gastric  fluid (pH 1.2,  enzyme free)  at  37°C
showed that tablets eroded upon contact with the release medium. The results also
showed that tablet composition had profound effect on the floating behavior and drug
release. All formulations showed suitable floating lag time (20 s), with duration of
floating more than 8 h. The drug release from those tablets was sustained over 8 hr.
17. N.M. Patel et al (2008)  studied the influence of content of polyethylene oxide and
ratio of lactose to starch 1500 on Dipyridamole release from self correcting flouting
matrix  tablets  using  3"  full  factorial  design.  Tablets  were  evaluated  for  in  vitro
floating ability and drug release study using USP 24 type II apparatus using 0.1 N
HCI at 100 rpm and temperature of 37±0,5''.  Multiple regression analysis and two
way  analysis  of  variance  followed  by  Tukey  test  were  performed  for  dependent
variables. All formulations floated within 2 min regardless of factors studied and had
total floating time of more than 12 h and follows zero order release.
18. Leopoldo Villafuerte-Robles et al (2009) developed a controlled release formulation
of Captopril, floating tablets,  and studied the in vitro sustained release of captoprill
varying  the  proportions   of   Metolose  SH400 and  bicarbonate,  Floating  behavior
studying at two different compaction pressures at (155Mpa&165Mpa). Other studied
variables include the kinetics of the hydration volume, the matrices floating time and
the matrix density. The results show that matrices compacted at 55 MPa float in the
dissolution medium for more than 8 h while those compacted at 165 MPa. The matrix
density is lower when compacted at 155 MPa. The drug release constant (k) decreases
and the exponent indicative of the release mechanism (n) increases with increasing
polymer contents. 
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19. Subhabrata  Ray  et  al  (2008)  formulated  Metformin  hydrochloride  floating
microspheres.  by  non-aqueous  emulsification  solvent  evaporation  technique  using
Ethyl  cellulose  as  the  rate  controlling  polymer  and  Evaluation  of  Floating  Drug
Delivery  System  (FDDS)  in  vitro,  prediction  of  the  release,  and  optimization  of
floatation and drug release pattern to match target release profile was investigated in
vitro floatation and release studies. floating time (> 8 hr) and the best results were
obtained at the ratio of drug: polymer: solvent (250:750:12 and 250:146.45:9 [mg :
mg : ml]), when both the batches were mixed in equal proportions. 
20. Javed Ali et al (2006)  formulated hydro dynamically balanced system for celecoxib
as single-unit floating capsules. Various grades of low-density polymers were used.
The capsules were prepared by physical  blending of celecoxib and the polymer in
varying ratios. The formulation was optimized on the basis of in vitro buoyancy and
in vitro release in citrate phosphate buffer pH 3.0 (with 1% sodium lauryl  sulfate).
Capsules prepared with polyethylene oxide 60K and Eudragit RL100 gave the best in
vitro percentage release and were used as the optimized formulation. By fitting the
data into zero-order, first-order, and Higuchi models, we concluded that the release
followed zero-order kinetics.
21. D.M.  Patel  et  al  (2003)  developed  carbamazepine  Floating  tablets  using  melt
granulation  technique.  Bees  wax,  Hydroxy  propyl  Methyl  cellulose,  sodium
bicarbonate and ethyl cellulose were used as matrixing agent, gas-generating agent
and  floating  enhancer,  respectively.  A  simplex  lattice  design  was  applied  to
investigate the formulation variables i.e.  amount of hydroxypropyl  methylcellulose
(X1), ethyl cellulose  (X2)  and sodium bicarbonate (X3). The floating lag time (Flag),
time required for 50% (t50) and 80% drug dissolution (t80) were taken as responses.
Results of multiple regression analysis indicated that, low level of X1, and X2 and high
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level of X3 should be used to manufacture the tablet formulation with desired in-vitro
floating time and dissolution. 
22. Mukesh C. Gohel et al (2003) prepared gastroretentive tablets of rifampicin (150
mg) by the wet granulation method using hydroxypropyl  methylcellulose,  calcium
carbonate,  and polyethylene glycol 4000. to minimize degradation of rilampicin in
acidic medium and to modulate the release of rifampicin in the stomach and isoniazid
in the intestine.. The in vitro drug release and in vitro drug degradation studies were
performed.  Rifampicin was  released  over  4 hours  by zero-order  kinetics from the
novel dosage form. More than 90% of isoniazid was released in alkaline medium in
30 minutes
23. Shashi  Kiran  Mishra  et  al  (2005)  formulated  gastro  retentive  controlled  release
system of loratadine was to increase the residence time in stomach and to modulate
the release behaviour of the drug. Oil entrapped floating microbeads prepared by the
emulsion gelation method were optimized by 23 factorial design and a polymer ratio
of 2.5:1.5 (pectin/sodium alginate) by mass, 15% (m/V) of oil (mineral oil or castor
oil)  and  0.45  mol  L–1  calcium  chloride  solution  as  the  optimized  processing
conditions for the desired buoyancy and physical stability. In vitro drug release in the
fed state conditions demonstrated sustained release of loratadine for 8 h, which best
fitted the Peppas model with  n  < 0.45. The ethyl  cellulose coating on microbeads
optimized  by22  factorial  design  resulted  in  a  controlled  release  formulation  of
loratadine that provided zero-order release for 8 h.
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3. AIM AND PLAN OF WORK
The  proposed  formulation  is  developed  by  considering  the  drawbacks
associated with the conventional controlled drug delivery system.
The formulation may remained in the stomach and / or upper part of GIT for
prolonged period of time thereby giving sufficient time for drug candidate to achieve
maximum bioavailability and reduce unwanted side effects by minimizing or avoiding
drug release at unfavorable site.
The aim of the present dissertation work is to sustain the release of drug due to
floating in stomach at acidic pH 1.2 up to 12 hrs.
Department of Pharmaceutics JKKMMRF College of pharmacy35
Chapter 3 Aim and Plan Of Work
3.1. PLAN OF WORK
1. Literature survey
2. Preformulation studies
• Selection of drug.
• Compatibility study using Fourier Transform Infrared Spectrophotometer.
• Analytical characterization of the drug.
• Selection of the excipients.
• Characterization of the excipients.
3.  Standard calibration curve of drug
4. Formulation development
• Formulation of the floating tablet.
• Effect of the formulation variables on the drug release, swelling and floating
properties.
4. Evaluation of tablets
• Tablet characteristics.
• In vitro Buoyancy study.
• Water uptake. 
• In vitro drug release studies of tablets.
5.       Study of release kinetics.
6. Stability study of the optimized batch.
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7.     In vivo confirmation of Buoyancy.
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4. MATERIALS AND METHODS
4.1.  Materials:
Table No.1: List of Chemicals Used
SR.NO. MATERIAL USED SUPPLIER
1. RANOLAZINE MICRO LABS Ltd.
2. HYDROXY  PROPYL METHYLCELLULOSE
YARROW CHEM
PRODUCTS MUMBAI,
INDIA.
3. CARBOPOL 934P
YARROW CHEM
PRODUCTS MUMBAI,
INDIA.
4. CHITOSAN COCHIN FISHERIESDEPT, KERALA.
5. SODIUM BICARBONATE THOMAS BAKER Pvt Ltd,MUMBAI.
6. MICROCRYSTALLINE CELLULOSE THOMAS BAKER Pvt Ltd,MUMBAI.
7. MAGNESIUM STEARATE THOMAS BAKER Pvt Ltd,MUMBAI.
8. TALC THOMAS BAKER Pvt Ltd,MUMBAI.
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4.2. Equipments:
 Table No.2: List of Instruments Used
Instrument Used Model No. Make
FTIR Spectrophotometer 8400S Shimadzu, Japan
UV–Visible
Spectrophotometer UV – 3000
+ LAB INDIA
Tablet Compression Machine Mini Press Rimek
Tablet Dissolution Tester
USP (XXIII) DS-8000 LAB INDIA
Environmental test chamber JRIC – 11A Oswald
Electronic Balance AGN-303EC AXIS
Tablet hardness tester N.S Monsanto
Roche's friabilator N.S Scientific
Hot air oven PYROCON York Scientific Ind.,Mumbai
Digital pH meter PHAN LAB INDIA
Melting Point apparatus N.S Biotech India Ltd.
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4.3. DRUG PROFILE
4.3.1 Ranolazine 
Ranolazine is an anti-ischemic and anti-anginal drug, designed to act without
reducing heart rate or blood pressure indicated for the treatment of chronic angina in
patients who have failed to respond to prior angina therapies.
4.3.2 Structure of Ranolazine:
4.3.3 Molecular formula: C24H33N3O4
4.3.4 Relative Molecular Mass:   427.54
4.3.5 Chemical Name: N-(2, 6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-
methoxyphenoxy) propyl] piperazin-1yl] acetamide.
4.3.6 Appearance: Ranolazine is a white to off-white solid.
It is odourless.
4.3.7 Physical Properties of Ranolazine: Below is a table of some of the physical
properties of Ranolazine. 
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Table No. 3: Physical Properties of Ranolazine
Melting Point 117-122oC
Dissociation Constant (pKa) 14.25 at 24oC
Partition Coefficent (Log P (octanol)) 2.08
Solubility
Water Very Slightly Soluble
Ethanol/Methanol Soluble
Ether Practically Insoluble
4.3.8 Pharmacokinetics:
Pharmacokinetic data of Ranolazine is given below:
Table No. 4: Pharmacokinetic Data of Ranolazine
Parameters Value
Availability (oral) % 73%
Urinary excretion (%) 75%
Bound in plasma (%) 62%
Clearance (ml. min-1. kg-1) 5.33ml/min/kg
Volume of distribution (liter / kg) 1.57L/kg
Half life (hr.) 1.4 - 1.9hrs
Effective concentration 2 – 6µmol/l
Absorption and distribution:
After  oral  administration,  a  peak  plasma  concentration  of  Ranolazine  is
reached between 2 and 5 hours. After  oral  administration of  14C-Ranolazine as a
solution, 73% of the dose is systemically available as Ranolazine or metabolites.
The bioavailability of Ranolazine from the extended dosage form relative to that
from a  solution  of  Ranolazine  is  76%.  Because  Ranolazine  is  a  substrate  of  P-
glycoprotein (P-gp), inhibitors of P-gp may increase the absorption of Ranolazine.
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Food especially high fat breakfast has no important effect on the Cmax and AUC of
Ranolazine. Therefore, Ranolazine may be taken without regard to meals. Over the
concentration range of 0.25 to 10 µg/mL, Ranolazine is approximately 62% bound
to human plasma proteins. 
Protein binding:
Over  the  concentration  range  of  0.25  to  10  µg/mL,  Ranolazine  is
approximately 62% bound to human plasma proteins. 
Metabolism: 
Ranolazine is metabolized rapidly and extensively in the liver and intestine.
The pharmacological  activity of  the metabolites  has  not been well  characterized.
After dosing to steady-state with 500 mg to 1500 mg twice a day the four most
abundant metabolites in plasma have AUC values ranging from about 5 to 33% that
of  Ranolazine.
Ranolazine  is  metabolized  mainly  by  CYP3A  and  to  a  lesser  extent  by
CYP2D6. 
Elimination:
Approximately 75% of the dose is excreted in urine and 25% in feces. Less
than 5% is excreted unchanged in urine and feces.[29]
Half-life:
           Half-life of Ranolazine was found to be 1.4 -1.9 hours. [28]
Mechanism of action:
The mechanism of action of Ranolazine is  unknown. Initially,  Ranolazine
was thought to exert its therapeutic efficacy primarily through partial inhibition of
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fatty  acid  oxidation.   These  pharmacological  effects,  however,  were  generally
observed at concentrations in excess of therapeutic plasma concentrations in human
clinical trials (>10 µmol/L). More recent evidence suggests that Ranolazine reduces
calcium overload  in  the  ischemic myocyte  through inhibition  of  the  late sodium
current (INa). Myocardial ischemia produces a cascade of complex ionic exchanges
that can result in intracellular acidosis,  excess cytosolic Ca2+,  myocardial  cellular
dysfunction, and, if sustained, cell injury and death Thus, Ranolazine is a relatively
selective inhibitor for late INa. In isolated ventricular myocytes in which the late INa
was  pathologically  augmented,  Ranolazine  prevented or  reversed  the  induced
mechanical  dysfunction,  as  well  as  ameliorated abnormalities  of  ventricular
repolarization.
 Ranolazine inhibition  of  late  INa is  discernible  at  therapeutic  plasma
concentrations in healthy cells, particularly in M cells and Purkinje fibers, where this
current is most prominent. However, in healthy nonischemic, nonfailing myocytes,
where the contribution of late INa is small, the drug does not have a measurable effect
on cardiovascular performance at therapeutic plasma concentrations. In patients with
chronic  angina and  demand-induced  ischemia,  Ranolazine  has  the  potential  to
partially  disrupt  the  consequences  of  cell  hypoxia  during  transient myocardial
ischemia by reducing excess late Na+ influx, thereby reducing calcium overload and
ultimately  reducing  the  concomitant increase  in  left  ventricular  wall  tension.
Reduction  in  diastolic left  ventricular  wall  tension  would  decrease  myocardial
oxygen requirements  in  marginally  ischemic  myocytes  and  has  the  potential to
reduce  vascular  compression, allowing more coronary blood flow to the affected
area. Additional research is necessary to confirm this latter hypothesis. [30][31]
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Fig.3.1.1. Positive feedback during ischaemia
Precautions:
Co-administration  of  Ranolazine  and  Digoxin  increases  the  plasma
concentrations of Digoxin by approximately 1.5-fold and the dose of Digoxin may
have to be reduced accordingly. The dose of other P-gp substrates may have to be
reduced  as  well  when Ranolazine  is  co-administered.  Ranolazine can  inhibit  the
activity of CYP2D6 and thus the metabolism of drugs that are mainly metabolized
by  this  enzyme  may  be  impaired  like  tricyclic  antidepressants  and  some
antipsychotics, and exposure to these drugs increased. The dose of such drugs may
have to be reduced when Ranolazine is co-administered.
Side effects:
In controlled clinical trials of angina patients, the most frequently reported
treatment-emergent  adverse  events  occurring  more  often  with  Ranolazine  than
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placebo, were  dizziness (6.2%),  headache (5.5%),  constipation (4.5%), and  nausea
(4.4%). In open-label, long-term treatment studies, a similar adverse event profile
were observed in patients treated with Ranolazine.
About  6% of  patients  discontinued  treatment  with  Ranolazine  due  to  an
adverse  event  in controlled studies  in angina  patients compared  to  about 3% on
placebo.  The  most  common  adverse  events  that  led  to  discontinuation  more
frequently  on  Ranolazine  than  placebo  were  dizziness  (1.3% versus  0.1%),  and
nausea (1%  versus  0%),  asthenia,  constipation and  headache (each  about  0.5%
versus 0%). 
Cardiac disorders – palpitation 
Ear and labyrinth disorders – tinnitus, vertigo 
Gastrointestinal disorders- abdominal pain, dry mouth, vomiting
Respiratory, thoracic and mediastinal disorders- dyspnea 
Drug interaction:
Pharmacokinetic Interactions: Effects of Other Drugs on Ranolazine:
Ketoconazole:
As  a  potent  inhibitor  of  CYP3A,  Ketoconazole  200  mg  b.i.d.  increases
average  steady-state  plasma  concentrations  of  Ranolazine  3.2-fold.  Ranolazine
should not be used during treatment with Ketoconazole.
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Diltiazem:
As a moderate inhibitor of CYP3A, Diltiazem 180 to 360 mg daily causes
dose-dependent mean increases in average Ranolazine steady-state concentrations of
about 1.8- to 2.3-fold.
Verapamil:
Verapamil  120  mg  t.i.d.  increases  Ranolazine  steady-state  plasma
concentrations about 2-fold.
Cimetidine:
Co-administration of Cimetidine does not increase the plasma concentrations
of Ranolazine. No dose adjustment of Ranolazine is required in patients treated with
Cimetidine.
Rifampin:
Rifampin 600 mg q.d. decreases the plasma concentration of Ranolazine by
approximately  95%.  Co-administration  of  Ranolazine  and  Rifampin  should  be
avoided.
Digoxin:
Co-administration of Digoxin does not increase the plasma concentration of
Ranolazine. No dose adjustment of Ranolazine is required in patients treated with
Digoxin.
Paroxetine:
Paroxetine,  a  potent  inhibitor  of  CYP2D6,  increased  average  steady-state
plasma concentrations of Ranolazine 1.2-fold. No dose adjustment of Ranolazine is
required in patients treated with Paroxetine or other CYP2D6 inhibitors.
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Pharmacodynamic Interactions: Effects of Ranolazine on Other Drugs
Digoxin:
As  a  result  of  an  interaction  at  the  P-gp  level,  co-administration  of
Ranolazine  and  Digoxin  results  in  a  1.5-fold  elevation  of  Digoxin  plasma
concentrations. The dose of Digoxin may have to be adjusted when Ranolazine is
co-administered with Digoxin.
Simvastatin:
Co-administration of Ranolazine and Simvastatin results in about a 2-fold
increase in plasma concentrations of Simvastatin, and its active metabolite.
Warnings:
QT Prolongation:
Ranolazine has been shown to prolong the QTc interval  in a dose-related
manner.  While  the  clinical  significance  of  the  QTc prolongation  in  the  case  of
Ranolazine is unknown, other drugs with this potential have been associated with
torsades de pointes-type arrhythmias and sudden death.
Tumor Promotion:
A published study reported that Ranolazine promoted tumor formation and
progression to malignancy when given to transgenic APC(min/+) mice at a dose of
30 mg/kg twice daily.
Indication:
Ranolazine  is  indicated  for  the  treatment  of  chronic  angina.  Because
Ranolazine prolongs the QT interval, it should be reserved for patients who have not
achieved an adequate response with other antianginal drugs. Ranolazine should be
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used  in  combination  with  Amlodipine,  beta-  blockers  or  nitrates.  The  effect  on
angina rate or exercise tolerance appeared to be smaller in women than men.
Dosage and Administration:
Ranolazine dosing should be initiated at 500 mg b.i.d. and increased to 1000
mg b.i.d.,  as  needed,  based  on  clinical  symptoms.  The maximum recommended
daily dose of Ranolazine is 1000 mg b.i.d. Baseline and follow-up ECGs should be
obtained to evaluate effects on QT interval.
The  concomitant  use  of  Ranolazine  with  other  commonly  administered
cardiovascular  medications  like  Amlodipine,  beta-blockers,  nitrates,  anti-
hypertensive  agents  is  well-tolerated.  If  a  dose  of  Ranolazine  is  missed,  the
prescribed dose should be taken at the next scheduled time. The next dose should
not be doubled. Ranolazine may be taken with or without meals. Ranolazine tablets
should be swallowed whole and not crushed, broken, or chewed. 
Over dosage:
No cases of intentional or accidental overdose with Ranolazine have been
reported.  In  the  event  of  overdose,  the  expected  symptoms  would  be  dizziness,
nausea/vomiting, diplopia, paresthesia, and confusion. Syncope with prolonged loss
of consciousness may develop. Because the QTc interval increases with Ranolazine
plasma concentration, continuous ECG monitoring may be warranted in the event of
overdose. If required, general supportive measures should be initiated.[32]
4.4 POLYMER PROFILE
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HYDROXY PROPYL METHYL CELLULOSE [33]
Chemical Name: Cellulose 2- hydroxy propyl methyl ether
Synonym: Cellulose, Hypromellose, 2 – Hydroxypropylmethyl ether, Methyl 
hydroxy propyl cellulose, Methocel, Pharmacoat, Metolose.
Structure:
                                   Figure 6. Hydroxypropyl methylcellulose.
                       Mixed ether of cellulose with some of the hydroxy groups in the form 
of methyl ether and some in the form of the 2-hydroxy propyl ether. Several grades 
of hydroxypropyl methylcellulose are distinguished by appending a number 
indicative of the apparent viscosity, in millipascal, of a 2% w/w solution measured 
at 20°C. Hypromellose defined in the USP 25 specifies the substitution type by 
appending a four digit number to the nonproprietary name, e.g. hypromellose 1828. 
The first two digits refer to the approximate percentage content of the methoxy 
group (OCH3). The second two digits refer to the approximate percentage content of 
hydroxypropoxy group [OCH2 CH C (OH) CH3], calculated on a dried basis. 
Molecular weight is approximately 10,000 – 15, 00,000.
Description: It is a white, yellowish white or greyish white, practically odorless, 
fibrous powder or granules.
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Physical Properties
Solubility: Soluble in cold water, forming a colloidal solution; practically insoluble 
in hot water, dehydrated alcohol, chloroform and ether. 
pH: A 1% w/w solution has a pH of 5.5 to 8.0.
Melting Point: Browns at 190-200°C; chars at 225-230°C; Tg is at 170-180°C.
Bulk Density: 0.341 g/cm3 
Tapped Density: 0.557 g/cm3
Enzyme Resistance: Comparatively enzyme resistant
Gel Formation: Undergoes a reversible transformation from solution to gel upon 
heating and cooling respectively.
Gel Point: 50 – 90°C depending upon the grade
Ash Value: 1.5 – 3 % depending upon the grade
Specific Gravity: 1.3
Surface Activity: Provides some surfactant activity in solutions, surface tension for 
such solutions range from 42 – 56 dynes/cm.
Storage: Store in well-closed containers.
Drug Excipients Interactions: Hydroxypropyl methylcellulose is incompatible 
with some oxidizing agents.
Safety: Hydroxypropyl methylcellulose is generally regarded as a nontoxic and 
nonirritant material although excessive oral consumption may have a laxative effect.
Pharmaceutical Uses: 
HPMC is widely used in oral and topical pharmaceutical formulations. It is 
used as tablet binder, for film coating and in sustained release preparations. 
Department of Pharmaceutics                      JKKMMRF College of Pharmacy48
Chapter 4 Materials and Methods
Hypromellose is also used as a suspending and thickening agent in topical 
formulations, particularly ophthalmic preparations. It is also used as an emulsifier, 
suspending agent and stabilizing agent in topical gel and ointments.
CARBOPOL
Nonproprietary Names
• BP: Carbomers
• PhEur: Carbomers
• USP-NF: Carbomer
Synonyms
Acrypol;  Acritamer;  acrylic  acid  polymer;  carbomera;  Carbopol;  carboxy
polymethylene; polyacrylic acid; carboxyvinyl polymer; Pemulen; Tego Carbomer.
Functional Category
Bioadhesive  material;  controlled-release  agent;  emulsifying  agent;  emulsion
stabilizer; rheology modifier; stabilizing agent; suspending agent; tablet binder.
Structure:
Description
Carbomers  are  white-colored,  ‘fluffy’,  acidic,  hygroscopic  powders  with  a
characteristic slight odor. A granular carbomer is also available.
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Typical Properties
• Acidity/alkalinity:
• pH = 2.5–4.0 for a 0.2% w/v aqueous dispersion;
• pH = 2.5–3.0 for Acrypol 1% w/v aqueous dispersion.
• Density (bulk): 0.2 g/cm3 (powder); 0.4 g/cm3 (granular).
• Density (tapped): 0.3 g/cm3 (powder); 0.4 g/cm3 (granular).
• Dissociation constant: pKa = 6.0_0.5
• Glass transition temperature: 100–1058C
• Melting point: Decomposition occurs within 30 minutes at 2608C.
• Moisture content: Typical water content is up to 2% w/w.
• Solubility:  Swellable  in  water  and  glycerin  and,  after  neutralization,  in
ethanol (95%). Carbomers do not dissolve but merely swell to a remarkable
extent, since they are three-dimensionally crosslinked microgels.
• Specific gravity: 1.41
Applications in Pharmaceutical Formulation or Technology
Carbomers are used in liquid or semisolid pharmaceutical formulations as rheology
modifiers.  Formulations  include  creams,  gels,  lotions  and  ointments  for  use  in
ophthalmic,  rectal, topical  and vaginal preparations.
CHITOSAN
Chitosan is a hydrophilic cationic polyelectrolyte obtained by 
alkaline N-deacetylation of chitin. Chitin is the most abundant natural polymer next 
to cellulose and is obtained from crab and shrimp shells.
Molecular formula:  (C6H11NO4)n
Chemical structure:  
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Chemical name:  Poly-(1-4)-2-Amino-2-deoxy-ß-D-Glucan
Description:  
Chitosan is a chitin molecule obtained in the presence of NaOH. Cationic 
character, along with the presence of reactive functional groups in chitosan, has 
given it particular possibilities for utilization in controlled release technologies.
Presence of free amino groups, allow its conjugation with some drugs. 
Chitosan, a linear polyelectrolyte at acidic pH is soluble in variety of acids and 
interact with poly anionic counter ions. It forms gels with a number of multivalent 
anions and also with glutaraldehyde. It has a high charged density, i.e. one charge 
per glucosamine unit. 
Chitin is a high molecular weight linear polymer of N-acetyl-D-glucosamine 
(N-acetyl-2-amino-2-dioxy-D-glucopyranose) units linked by β-D (1, 4) bonds. It is 
highly insoluble in common solvents, resembling cellulose in its solubility and low 
chemical reactivity. Like cellulose, it naturally functions as a structural 
polysaccharide. It is most abundant in crustaceans, insects and Fungi. The skeletal 
shells of these crustaceans contain approximately 75% calcium carbonate and 15 - 
20 % chitin. 
Chitosan is non-toxic and easily bio absorbable with gel forming ability at 
low pH. Also, chitosan matrix formulations appear to float and gradually swell in 
acidic medium. 
Solubility:
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a. Chitosan is soluble in acidic solutions, soluble to a limited extent in dilute
inorganic acids except phosphoric and sulphuric acids. 
b. Soluble at pH values less than 7.0 but mainly in dilute acid. Preferably below
pH 6.0 and often in formic, acetic, tartaric, citric, lactic acids of 0.25 – 1 %
concentration. Dissolve readily in dilute solutions of most organic acids.
c. Insoluble in water, alkaline solutions at pH levels above 6.5 organic solvents.
d. It has gel forming properties in low pH range.
Important characteristics of Chitosan to be considered in the pharmaceutical 
formulations
a. Molecular weight
Low molecular weight – 150,000
High molecular weight – 600,000
b. Degree of deacetylation
Commercial deacetylated chitin is approximately 80 – 85 % deacetylated.
Degree of deacetylation necessary to obtain a soluble product must be 80 – 
85 % (or) higher i.e., acetyl content of the chitosan product must be < 4 – 
4.5%.
c. Viscosity
At concentration of 1.25 % in dilute acetic acid has a viscosity of 
1200 cps – good quality
160 cps – medium quality
161 cps – low quality
d. Crystallinity index, number of monomeric units (n), water retention value,
pKa, energy of hydration.
Pharmaceutical requirements of chitosan:
• Particle size - < 30 µm
• Density - between 1.35 and 1.40 g/cc
• pH - 6.5 – 7.5
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Chitosan can also be characterized in terms of its quality, intrinsic properties 
and physical forms. The quality characteristics of Chitosan are:-
• Levels of heavy metals and proteins
• Pyrogenicity
• Bio-burden
• Cytotoxicity 
• Clarity.
Biological properties:
• Biocompatibility (non-toxic, biodegradable, natural well tolerated by living
tissues)
• Bioactivity
• Wound healing acceleration
• Reduces blood cholesterol level
• Immune system stimulant
• Bacteriostatic 
• Haemostatic
• Fungistatic
• Spermicidal
• Anti-carcinogenic
• Anti-cholesteromic   
Chemical properties:
                Deacetylation : 40%-98%
Ash : Less than 1.5%
Loss on drying : Less than 10%
Inherent viscosity : < 200 mPas
Molecular weight :  50 kDa-2000 kDa
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Crystallinity index : ~70%
pKa : 5.5 - 6.5
Other properties:
• Cationic polyamine
• High charged density at pH < 6.5
• Adheres to negatively charged surfaces forms gels with poly-anions
• High molecular weight linear polyelectrolyte, viscosity, high to low
• Chelates certain transitional metals
• Amiable to chemical modification
• Reactive amino / hydroxyl groups
Storage conditions: 
 10kg net in plastic woven bags, or corrugated paper carton with plastic 
liners.
Chitosan and drug delivery: 
Drug release characterized by an initial burst effect probably due to the 
release of the drug which is adsorbed on the surface of the microspheres or 
nanoparticles.
Injectable route:  
Since chitosan is well tolerated by living tissues and is biodegradable, it has 
been recently envisaged for the controlled release or drugs administered parenterally
in the form of cross-linked microspheres and nanoparticles. It has been shown that 
drug diffusion from a chitosan matrix could be effectively controlled using a cross-
linking agent such glutaraldehyde, which leads to a diminished susceptibility of the 
polymer to lysozyme.
4.5 EXCIPIENT PROFILE
SODIUM BICARBONATE [34][35]
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Synonyms:
Baking soda; monosodium carbonate; sodium hydrogen carbonate; sodium
acid carbonate
IUPAC Name:
Carbonic acid monosodium salt
Empirical Formula: NaHCO3
Molecular Weight: 84.01
Pharmaceutical Application:
Sodium bicarbonate is generally used in pharmaceutical  formulations as a
source of carbon dioxide in effervescent tablets and granules. It is also widely used
to  produce  or  maintain  alkaline  pH  in  preparation.  In  effervescent  tablets  and
granules,  sodium bicarbonate  is  usually  formulated  with  citric  and  tartaric  acid
combinations of citric and tartaric acid often preferred in formulations as citric acid
alone produces a sticky mixture that is difficult to granulate, while if tartaric acid is
used  alone  granules  lose  firmness.  Sodium  bicarbonate  is  also  used  in  tablet
formulations to buffer drug molecules that are weak acids, thereby increasing the
rate  of  tablet  dissolution  and  reducing  gastric  irritation.  Additionally,  sodium
bicarbonate is used in solutions as a buffering agent for erythromycin,  lidocaine,
local  anaesthetic  solutions.  In  some parenteral  formulations (e.g.  niacin),  sodium
bicarbonate is used to produce sodium salt of the active ingredient that has enhanced
solubility. Sodium bicarbonate has also been used as a freeze drying stabilizer and in
toothpastes.
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Recently,  sodium  bicarbonate  has  been  used  as  a  gas  forming  agent  in
alginate  raft  systems  and  in  floating,  controlled  release  oral  dosage  forms  of
furosemide and cisapride. Therapeutically, sodium bicarbonate may be used as an
antacid, and as the source of bicarbonate anion in a treatment of metabolic acidosis.
Sodium bicarbonate may also be used as a component of oral rehydration salts and
as a source of bicarbonate in dialysis fluids.                      
Description:
Sodium bicarbonate occurs as an odourless, white, crystalline powder with
saline, slightly alkaline taste.
Typical Properties:
Density (bulk): 0.869 g/cm3
Density (tapped): 1.369g/cm3
Melting point: 270°C
Moisture content:
Below 80 % relative humidity,  the moisture content is less than 1% w/w.
Above 85% relative humidity sodium bicarbonate rapidly absorbs water and may
start to decompose with loss of carbon dioxide.
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Incompabilities:
Sodium bicarbonate reacts with acids, acidic salt and many alkaloidal salts,
with  the  evolution  of  carbon  dioxide.  In  liquid  mixtures  containing  bismuth
subnitrate, sodium bicarbonate reacts with the acid formed by hydrolysis of bismuth
salt.  In  solution,  sodium bicarbonate  has  been  reported  to  be  incompatible  with
many  drug  substances  such  as  ciprofloxacin,  amiodarone,  nicardipine  and
levofloxacin.
MICROCRYSTALLINE CELLULOSE
Nonproprietary Names:
BP: Microcrystalline Cellulose
JP: Microcrystalline Cellulose
PhEur: Cellulose, Microcrystalline
USP-NF: Microcrystalline Cellulose
 Synonyms:
Avicel  PH;  Cellets;  Celex;  cellulose  gel;  hellulosum  microcristallinum;
Celphere; Ceolus KG; crystalline cellulose; E460; Emcocel; Ethispheres; Fibrocel;
MCC Sanaq; Pharmacel; Tabulose; Vivapur.
Chemical Name:
Cellulose [9004-34-6]
 Empirical Formula and Molecular Weight:
(C6H10O5)n _36 000
where n is 220.
Structural Formula:
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Functional Category:
Adsorbent; suspending agent; tablet and capsule diluent; tablet disintegrant.
Applications in Pharmaceutical Formulation or Technology:
Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a
binder/diluent in oral tablet and capsule formulations where it is used in both wet-
granulation  and  direct-compression  processes.  In  addition  to  its  use  as  a
binder/diluent,  microcrystalline  cellulose  also  has  some  lubricant  and
disintegrantproperties that make it useful in tableting.
MAGNESIUM STEARATE [34]
Non-Proprietary Names
BP: Magnesium stearate; IP: Magnesium stearate
PhEur: Magnesii stearas; USPNF: Magnesium stearate
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Synonyms: Magnesium octadecanoate, octadecanoic acid, magnesium salt, stearic 
acid, magnesium salt.
Chemical Name and CAS Registry Number: Octadecanoic acid magnesium salt 
[557-04-0]
Empirical Formula: C36H70MgO4 
Molecular Weight: 591.34
The USPNF 23 describes magnesium stearate as a compound of magnesium 
with a mixture of solid organic acids that consists chiefly of variable proportions of 
magnesium stearate and magnesium palmitate (C32H62MgO4). The PhEur 2005 
describes magnesium stearate as a mixture of magnesium salts of different fatty 
acids consisting mainly of stearic acid and palmitic acid and in minor proportions 
other fatty acids.
Structural Formula
[CH3 (CH2)16COO]2Mg
Description
Magnesium stearate is a very fine, light white, precipitated or milled, 
impalpable powder of low bulk density, having a faint odour of stearic acid and a 
characteristic taste. The powder is greasy to touch and readily adheres to the skin.
Physical Properties :
Crystalline Forms: High-purity magnesium stearate has been isolated as a 
trihydrate, a dehydrate and an anhydrate.
Density (bulk): 0.159 g/cm3
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Density (tapped): 0.286 g/cm3
Density (true): 1.092 g/cm3
Flash point: 250°C
Flowability: Poorly flowing, cohesive powder.
Melting Range: 117–150°C (commercial samples); 126–130°C (high purity 
magnesium stearate).
Solubility: Practically insoluble in ethanol, ethanol (95%), ether and water; slightly 
soluble in warm benzene and warm ethanol (95%).
Specific Surface Area: 1.6–14.8 m2/g
Stability and Storage Conditions: Magnesium stearate is stable and should be 
stored in a well-closed container in a cool, dry place.
Pharmaceutical Application
Magnesium stearate is widely used in cosmetics, food and pharmaceutical 
formulations. It is primarily used as a lubricant in capsule and tablet manufacture at 
concentrations between 0.25% and 5.0% w/w. It is also used in barrier creams.
TALC33
Synonyms                 : Purified French Chalk, Purtalc, Soapstone. 
Description            : It is very fine, white to grayish-white 
colored odorless, impalpable, unctuous,
                                     crystalline powder.               
Functional categories : Glidant and lubricant in tablets and 
           capsules.
Solubility : Insoluble in water, organic solvent, dilute 
acid & alkalis.
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pH                              : 7.0 – 10.0  for a 20 % aqueous 
dispersion.
Loss on drying           : < 1.0 %
Hygroscopicity           : It absorbs insignificant amount of water at & 
relative humidities upto about 90 %. 
Stability and storage
Conditions : It is a stable material. It should be stored in a 
   Well-closed container in a cool, dry place.
Incompatibilities  : Incompatible with quaternary ammonium 
Compounds
Applications : It is widely used in oral solid dosage forms as a
Lubricant & diluents.  It is used as a dusting 
powder in topical use. Additionally used to 
clarify liquids and mainly used in food  and 
cosmetics products because of its lubricant  
properties.
4.5 PREFORMULATION STUDIES:    
4.5.1. Determination of Melting Point.
Melting  point  of  Ranolazine  was  determined  by  capillary  method.  Fine
powder of Ranolazine was filled in glass capillary tube (previously sealed on one
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end). The capillary tube is inserted into the melting point apparatus and observed the
temperature  at  which  drug  started  to  melt  by using the  thermometer  which  was
already immersed into the liquid paraffin in the apparatus.
4.5.2. Compatibility study:
          A successful formulation of a stable and effective solid dosage form depends
on  careful  selection  of  the  excipients  that  are  added  to  facilitate  administration,
promote the consistent release and bioavailability of the drug and protect it  from
degradation.  If  the  excipients  are  new  and  have  not  been  used  in  formulations
containing  the  active  substance,  the  compatibility  studies  are  of  paramount
importance.
FT-IR:
Compatibility of the Drug with the excipients was determined by subjecting
the  physical  mixture  of  the  drug  and  the  polymers  of  the  main  formulation  to
infrared absorption spectral analysis. Any changes in chemical composition of the
drug  after  combining  it  with  the  polymers  were  investigated  with  I.R.  spectral
analysis.
 Schematic representation of compatibility studies
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Procedure:
Weighed amount of drug (3mg) was mixed with 100mg of potassium bromide (dried
at  40-50oC).  The mixture  was taken  and compressed  under  10-ton pressure  in  a
hydraulic  press  to  form  a  transparent  pellet.  The  pellet  was  scanned  by  IR
spectrophotometer.
4.5.3 Drug–Polymer Interaction/Compatibility study using FTIR 
Fourier Transfer Infrared Spectroscopy
IR  has  been  the  method of  choice  to  probe  the  nature  and  extent  of
interaction in polymer blends. IR was used in the study because mixing of the two
components  at  molecular  level  will  cause  changes  in  oscillating  dipoles  of  the
molecules. If the drug and polymer interact then functional groups in FTIR spectra
will show band shift and broadening compared to that of pure compounds.
Method
Potassium  Bromide  disc  containing  drug,  polymer  and  their  physical
mixture were prepared to record the spectrum by using Shimadzu 8400S FTIR.
4.5.4 Total Ash Value
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Silica crucible was heated to red hot for 30 minutes, allowed to cool in a
dessicator and weighed.  Accurately weighed 1.0 g of each polymer was transferred
and distributed in crucible, dried at 100-105ºC for 1 h and ignited to constant weight
in a muffle furnace at 600±25ºC.  The crucible was allowed to cool in a dessicator
and weighed till constant weight has been attained.  Total ash value was calculated
with reference to the air dried sample.
4.5.5. Sulfated Ash
Silica crucible was heated to red hot for 10 minutes allowed to cool in a
dessicator and weighed. Accurately weighed 1.0 g of sample was transferred and
distributed in a crucible, and ignited until the substance was thoroughly charred. The
crucible was allowed to cool,  the residue was moistened with 1.00 ml of 0.2 M
sulfuric acid and ignited at about 600±25ºC, until the white fumes were no longer
evolved and ignited until all black particles has been disappeared.  Then the crucible
was allowed to cool and weighed till constant weight has been attained.
4.5.6 Loss on Drying
A glass  stoppered  shallow weighing bottle  dried  at  105ºC was taken and
accurately weighed sample was transferred to the bottle.  The sample was evenly
distributed by gentle sidewise shaking.  The loaded bottle was placed in an oven.
The stopper  was  removed and left  in  the  chamber  and the  sample was  dried  at
105ºC.  The sample was dried to constant weight.  After drying was completed, the
bottle was closed properly and allowed to cool at room temperature in a dessicator.
The weight of content was calculated.
4.5.7 pH of the solution: 
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A 1% W/V solution of different polymers and excipients were prepared and
pH of the solution was determined by pH meter.
4.5.8. Acid Insoluble Ash: 
The ash was boiled with 25 ml of 2 M HCl for 5 min., and the insoluble
matter  was  collected  on  an ashless  filter  paper,  washed  with  hot  water,  ignited,
cooled in a desiccator and weighed.
4.6   The Standard Calibration Curve of Ranolazine
Ranolazine was quantitatively analyzed by various techniques. In the present
study, Ranolazine was estimated by UV spectrophotometry method. 
4.6.1. Determination of λmax for: Ranolazine
Two different stock solutions of drug sample were prepared by dissolving
100.0 mg of drug in 100.0 ml of 0.1 N HCl and in 100.0 ml of phosphate buffer
solution  pH  (6.8),  solutions  were  further  diluted  and  analyzed
spectrophotometrically to determine λmax.
Observation: 
The λmax was found to be 272 nm.
4.6.2 Preparation of standard calibration curve of Ranolazine
4.6.3 In 0.1 N HCl
A. Preparation of 0.1 N HCl: 85 ml of conc. hydrochloric acid was diluted upto 1000
ml with distilled water, gives 1N solution. 10 ml of resulting solution was further
diluted up to 100 ml with distilled water gives 0.1 N HCl.
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B. Preparation of dilutions for standard curve:  Stock solution was prepared by
dissolving  100.0  mg of  Ranolazine  in  100.0  ml  of  0.1  N HCl solutions,
which was further diluted to give the solutions of concentration 5, 10, 15, 20
and 25 µg/ml respectively. Absorbance of these solutions were measured on
UV spectrophotometer at 272 nm and plotted against the concentration to
give the standard curve.
C. Changes in the height of solid and liquid layers were measured after every 24
hours.
4.6.5. In 6.8 pH Phosphate Buffer
A. Preparation of Phosphate Buffer  pH 6.8 : Accurately weighed quantity of
27.218 g of potassium dihydrogen phosphate was dissolved in distilled water
and diluted with distilled water upto 1000 ml. 50ml of above solution was
taken in a 200 ml volumetric flask, 22.4 ml of 0.2 M NaOH was added to the
solution and then diluted with distilled water upto volume.
B. Preparation of dilutions for standard curve:  Stock solution was prepared by
dissolving 100.0 mg of Ranolazine in 100.0 ml of 6.8 pH Phosphate buffer
solutions, which was further diluted to give the solutions of concentration 5,
10, 15, 20 and 25  µg/ml respectively.  Absorbance of these solutions were
measured  on  UV  spectrophotometer  at  272  nm  and  plotted  against  the
concentration to give the standard curve.
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4.7 Formulation of Floating Tablets of Ranolazine [37]
                         Fig. No. 16.Steps involved
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Compression
Blend either manually or by rotary press 
compressed into tablets
Preblend
Drug and a portion of excipients mixed
Mixing
Preblend mixed in a pestle mortor
Blending
Preblend and remaining excipients mixed
Sieving
Blend pass through different sieve for sizing
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Table No. 5: Composition of Ranolazine Floating Tablet
Batch
Code
Drug
(mg)
HPMC K 4
M (mg)
HPMC K 15
M (mg)
HPMC K 100
M (mg)
Carbopol 934
P (mg)
Chitosan
(mg)
Sodium
bicarbonate (mg)
Micro crystalline
cellulose (mg)
RF1 500 300  - -  - - 30 10
RF2 500 - 300 -  -  - 30 10
RF3 500  -  - 300  -  - 30 10
RF4 500 150  - - 150  - 30 10
RF5 500  - 150 - 150  - 30 10
RF6 500  -  - 150 150  - 30 10
RF7 500 150  -  -  - 150 30 10
RF8 500  - 150  -  - 150 30 10
RF9 500  -  - 150  - 150 30 10
RF10 500  - -  -  - 300 30 10
HPMC- Hydroxy propyl methyl cellulose. All the formulations contained 1% of Magnesium stereate and 1% Talc.
* Quantities are in milligrams.
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4.7.1. Preparation Floating Tablets of Ranolazine
Technology Applied: Direct compression.
The key ingredients included in the formulations are:
 Hydrophilic  Polymers:  HPMC  K4M,  HPMC  K15M,  HPMC  K100M,
Carbopol 934P and Chitosan to modify the pattern of Ranolazine release from
matrix.
 Effervescent agent: Sodium bicarbonate
 Filler: Micro Crystalline Cellulose
 Antiadherant: Talc
 Lubricant: Magnesium Stearate.
Procedure:
      Accurately weighed quantities of polymer and MCC for each batch were taken (in
a mortar and mixed geometrically, to this required quantity of Ranolazine was added 
and mixed slightly with pestle. Accurately weighed quantity of Sodium bicarbonate 
was taken separately in a mortar and powdered with pestle. The powder is passed 
through sieve no 40 and mixed with the Ranolazine blend which was also passed 
through sieve no 40. The whole mixture was mixed for 3 minutes. To this Magnesium
stearate was added and mixed for minutes, later Talc was added and mixed for 2 
minutes. The mixture equivalent to 850mg was compressed into tablets with 13.5mm 
capsulate punches (A total weight of 170g powder blend was required in each batch 
containing 100 tablets). The composition of various formulations was given in    
Table 5.
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4.8 Evaluation of powder characteristics [35][36]
A) Pre-Compression Parameters: 
4.8.1. Angle of Repose
Angle of response is the angle of inclination, formed to the flat surface by
the bulk of granules when it is allowed to flow under gravitational force from a fixed
height.  It is a characteristic of granule flow properties and is calculated by using the
formula.
θ = tan -1 (h/r)
Where 
θ - Angle of repose
h - Height of granule above flat surface
r - Radius of circle formed by the granule pile 
4.8.2. Compressibility Index
It  is  also a  characteristic  of  granule  flow properties.  The  bulk density and
tapped  density  was  measured  and  compressibility  index  was  calculated  using  the
formula, 
C.I. = { ( Pt – P0 ) / Pt  } × 100
Where, Pt = tapped density
Ρ0 = bulk density
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4.8.3. Hausner Ratio
Tapped density and bulk density were measured and the hausner  ratio was
calculated using the formula, 
Hausner ratio = Pt / P0
Where, Pt  = tapped density
Ρ0 = bulk density
A) Post-Compression Parameters:
4.9 Evaluation of Tablets [40]
4.9.1. Hardness 
Tablet hardness has been defined as the force required for breaking a tablet in
a diametric compression test.  A tablet was placed between two anvils of the hardness
tester (Monsanto type), force was applied to the anvils, and the crushing strength that
caused the tablet to break was recorded.
4.9.2. Thickness
The  tablet  thickness  is  essential  for  consumer  acceptance  and  to  maintain
tablet to tablet uniformity. The thickness of the tablets was measured using vernier
caliper. It is expressed in mm. 5 tablets of each batch were picked randomly and its
thickness were measured individually. The thickness of the tablet is mostly related to
the tablet hardness
4.9.3. Friability 
Tablets  require  a  certain  amount  of  strength,  or  hardness  and resistance  to
friability, to withstand mechanical shocks of handling in manufacture, packaging and
shipping.  Preweighed tablet samples (20 tablets) were placed in the friabilator, which
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was then operated for 100 revolutions, dropping the tablets a distance of 6 inches with
each revolution.  The percentage friability was calculated using the formula.
% friability = 100x
wtinitial
wtfinalwtinitial −
4.9.4. Weight variation test 
20 tablets were selected at  random and weighted individually.  The average
weight of each batch of tablet was calculated. Individual weights of the tablets were
compared  with the average  weight.   Since the tablets  weighed  over  100 mg,  I.P.
specifies that the tablets pass the test if not more than two of the individual weights
deviate from the average weight by more than 7.5%.
4.9.5. Drug content 
To evaluate tablets potential for efficacy, the amount of drug per tablet needs
to be monitored from tablet to tablet, and batch to batch.  To perform the test, ten
tablets  from  each  batch  were  weighed  and  powdered.  Powder  equivalent  to  the
average weigh of the tablet was accurately weighed and transferred into a 100 ml
volumetric flask and dissolved in a suitable quantity of distilled water. The solution
was made up to the mark and mixed well. A portion of the sample was filtered and
analyzed by a UV spectrophotometer at 272 nm.
4.9.6. In vitro Buoyancy Study:
The  time  taken  for  dosage  form  to  emerge  on  surface  of  medium  called
floating lag time (FLT) and duration of time by which the dosage form constantly
emerge on surface of medium called total floating time.(TFT).
Procedure
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One  tablet  from  each  formulation  batch  was  placed  in  USP  type  II
dissolution apparatus  containing 900 ml  of  0.1N HCl using paddle at  a  rotational
speed of 50 rpm. The temperature of medium was maintained at 37±2  oC. the time
taken for tablet to emerge on surface of medium and the duration of time by which the
tablet constantly remain on surface of medium was noted.
Fig. 18: Floating behavior of Ranolazine Floating Tablet (RF8)
                 At initial time                                                 After 30 sec
4.10 Water Uptake Studies:
4.10.1. Study of Swelling behaviour
Swelling of tablet excipients particles involves the absorption of a liquid
resulting in an increase in weight and volume. Liquid uptake by the particle may be
due  to  saturation  of  capillary  spaces  within  the  particles  or  hydration  of
macromolecule.  The  liquid  enters  the  particles  through  pores  and  bind  to  large
molecule, breaking the hydrogen bond and resulting in the swelling of particle. The
extent of swelling can be measured in terms of % weight gain by the tablet.
4.11.   In-Vitro Dissolution Study [30]:
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Dissolution of the tablet of each batch was carried out using USP type I
apparatus (Basket type).
Procedure
Nine hundred ml of 0.1 N HCl was filled in a dissolution vessel and the
temperature of the medium was set at 37±2oC.106 Tablet was placed in each dissolution
vessel and rotational speed of paddle was set at 50 rpm. The 5 ml of sample was
withdrawn at  predetermined time interval  for  24 hours  and same volume of  fresh
medium was replaced. The samples were analyzed for drug content against 0.1 N HCl
as blank at λ  max  of 272 nm using double beam UV visible spectrophotometer. The
content of drug was calculated using the equation generated from standard curve. The
% cumulative drug release was calculated.
4.12. Study of drug release kinetics [29]:
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For finding out the mechanism of drug release from floating tablets, the
dissolution data obtained from the above experiments were treated with the different
release kinetic equations.
Zero order release equation
Q = K0 t ______________ (1)
First order equation
In Q = Kf  t ______________ (2)
Higuchi‘s square root of time equation
Q = KH t ½ _______________ (3)
Korsmeyer and Peppas equation
F = (Mt / M) = Km tn _________ (4)
Where, 
Q = amount of drug release at time t.
Mt = drug release at time t.
M = total amount of drug in dosage form
F = fraction of drug release at time t.
K0 = zero order release rate constant.
Kf = first order release rate constant.
KH = Higuchi square root of time release rate constant.
Km = constant depend on geometry of dosage form.
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N = diffusion exponent indicating the mechanism of drug 
release, where for cylinder value of n is 0.45 indicate 
fickian diffusion, between 0.45 and 0.89 indicate 
anomalous transport and 0.89 indicate case – II transport.
In  order  to study the drug release kinetics of the examined tablets,  the
dissolution profiles of formulations were analyzed according to zero-order, first order,
Higuchi's square root and Peppas korsmeyer's equations. 
4.13. Stability Studies:[29]
Stability testing is an integral part of formulation development. It  generates
information on which to base proposals for the shelf lives of drug substances  and
products and their recommended storage conditions. Stability data also are a part of
the dossier submission to regulatory agencies for licensing approval.
Stability  testing  ensures  that  a  drug  substance  will  be  safe  and  effective
throughout the shelf life of the product.  However,  meeting the potency and purity
profiles established in the compendia can be challenging as pharmaceutical products
become increasingly complex and diverse.
The optimized formulation RF8 packed in PVC blister pack then, they were
stored at three different temperatures 40C±20C, 270C±20C and 450C±20C for 45 days at
RH  75±5%.  At  15  days  intervals,  the  tablets  were  evaluated  for  their  physical
appearance, drug content and drug excipients compatibility at specified intervals of
time.
JKKMMRF College of Pharmacy Department of Pharmaceutics76
Chapter 4 Materials and Methods
 4.14. In-vivo confirmation of buoyancy by using radiographic studies[36] 
         In-vivo study was performed in albino rabbits using X-Ray imaging technique.
Prior  permission  was  taken  from  institutional  animal  ethical  board
(Reg.No.  JKKMMRFCP/IAEC/2012/010).   For  this study the tablets  of optimized
batch  (RF8)  was  prepared  by  replacing  half  of  the  amount  of  drug  with  barium
sulfate.  Animals  were  fasted  for  12  hrs  before  study  apart  from  drinking  water.
Tablets were administered orally. Radiographs were obtained at predetermined time
intervals (30mins, 60 mins, 120 mins, 180 mins and 300mins)
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5. RESULTS AND DISCUSSION
5.1 Preformulation study: 
Table No. 6: Analysis Report of Ranolazine
Test Specification of IP Results
Character White or almost white powder. White granular powder
Solubility
Soluble in ethanol; sparingly
soluble in water; slightly soluble
in dichloromethane; practically
insoluble in ether
Insoluble in hot water, in
acetone, in ethanol, in ether
and in toluene.
IR Spectra
The potassium bromide disc
contain drug was prepared to
record the spectrum by using
FTIR spectrophotometer
The spectrum showed all
prominent peaks of
Ranolazine
Melting Point 1170C – 1220C 1190C
Loss on Drying 1.0% 0.68%
Sulphated Ash 0.1% 0.1%
Bulk Density N.S. 0.51
Tapped Density N.S. 0.327
Compressibility Index N.S. 15.84
Hausner Ratio N.S. 1.163
                                                                                    
N.S.  Not Specified
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Discussion: 
Preformulation studies indicate that the drug (Ranolazine) passes the identification
test specified in IP. The physical parameters of drug as well as excipients concluded that
these were considerably good to formulate the tablet by direct compression technique. The
value of Carr’s Index from 5 – 16 indicates excellent to good flow of powder. Similarly
value of Hausner ratio (< 1.25) and Angle of repose (< 25o) indicates good flow properties
of drug. 
5.1.1. Drug–Polymer Interaction/Compatibility study using FTIR
Table No. 7: FTIR Spectral Analysis
S. No Functional groups
Characteristic peaks
(nm) Observed peaks(nm)
Stretching Bending Stretching Bending
1 N–H 3500 – 3100 Near 800 3327.32 829.82
2 C=O 1680 – 1630 - 1685.84 -
3 O–H 1440–1220 - 1334.78 -
4 –O− 1250–1040 - 1103.32 -
The different peaks of drug, polymer and their physical mixture indicate all groups
and characteristics of the drug were not altered. There is no significant interaction in drug
and  polymer.
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Graph No.1: FTIR Spectral Analysis of Ranolazine
Graph No.2: FTIR spectral analysis of Physical mixture of Drug and polymer
(Ranolazine +HPMC K4M)
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Graph No.3: FTIR spectral analysis of Physical mixture of Drug and polymer
(Ranolazine +HPMC K15M)
Graph No.4: FTIR spectral analysis of Physical mixture of Drug and polymer
(Ranolazine +HPMC K100M)
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Graph No.5: FTIR spectral analysis of Physical mixture of Drug and polymer
(Ranolazine +Carbopol 934 P)
Graph No.6: FTIR spectral analysis of Physical mixture of Drug and polymer
(Ranolazine +Chitosan)
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Discussion: 
Physical mixture of drug and polymer was characterized by FTIR spectral analysis
(Graph  1,  2,  3,  4,  5,  and  6)  for  any  physical  as  well  as  chemical  alteration  of  drug
characteristics.  From  results,  it  was  concluded  that  there  was  no  interference  in  the
functional group as the principle peaks of Ranolazine were found to be unaltered in the drug
polymer physical mixture.
5.2  Standard Calibration Curve of Ranolazine
Graph 7: Calibration curve of Ranolazine in 0.1 N HCl
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Discussion: 
From the scanning of drug in 0.01 N HCl, it was concluded that the drug had λ max of
272.0 nm and which was exactly similar as reported. From the standard curve of 0.1 N HCl
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it was observed that the drug obeys Beer – Lambert’s law in concentration range of 0 – 60µg
/ ml in the medium.
5.3 Pre-Compression Parameters:
Table No. 8: Characteristics of Final blend
Discussion:
Table 8 indicates the powder characteristics of various batches of floating tablets. 
Various formulations show good flow properties. Results of Angle of repose (220.77′ – 
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Formulations Angle of 
repose 
(θ)
Compressibility
Index or
Carr’s Index (%)
Hausner’s ratio
RF1 260.86′ 14.16 1.152
RF2 230.48′ 14.10 1.127
RF3 240.49′ 15.50 1.154
RF4 270.39′ 15.92 1.165
RF5 220.77′ 14.34 1.152
RF6 250.15′ 15.01 1.176
RF7 240.12′ 14.18 1.125
RF8 250.52′ 15.04 1.177
RF9 220.35′ 14.35 1.152
RF10 240.65′ 15.45 1.185
Chapter 5 Results and Discussion
270.39′), Carr’s index (14.34 – 15.92), Hausner’s ratio (1.165-1.177) shows satisfactory 
results, which is required for better  bioavailability
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5.4.1. Physical Properties
Table No. 10: Physical Properties of each Batch of Ranolazine Floating Tablets
Batch
code
Weight
variation
(mg)
Thickness
(mm) Hardness(kg/cm
2) Friability(%)
Drug
uniformity
(%)
RF1 848±1.81 4.2 7.5 0.52 98.45
RF2 850±1.53 4.5 7.72 0.54 98.41
RF3 849±1.70 4.12 7.89 0.57 98.57
RF4 852±2.35 4.75 7.56 0.56 97.74
RF5 848±1.84 4.2 7.34 0.6 98.12
RF6 851±2.02 4.71 7.62 0.63 97.43
RF7 849±1.67 4.32 7.1 0.54 99.21
RF8 850±1.58 4.19 7.23 0.57 99.14
RF9 848±1.86 4.72 7.55 0.61 98.65
RF10 851±2.11 4.31 7.37 0.64 98.15
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Discussion: 
From the physical parameters (Table 10) of each batch, it was concluded that the
tablets of all batches had desirable physical characteristics. Results of Hardness of various
batches of prepared formulations (7.1 –7.89 kg / sq cm.) and Friability (0.52 – 0.64 %)
indicates that the tablets having sufficient strength to withstand physical abrasion. Tablets of
all batches pass the weight variation test as per the limits prescribed in IP. (5% deviation is
allowed for average weight of tablet X ≥ 250 mg).
5.4.2. In-vitro Buoyancy study:
Table 11: In-vitro Buoyancy study of Ranolazine Floating Tablets
Batch Code Floating Lag Time(Sec) Total Floating Time(Hours)
RF1 53 >10
RF2 41 >12
RF3 62 >12
RF4 364 >08
RF5 333 >10
RF6 431 >10
RF7 42 >12
RF8 32 >12
RF9 53 >12
RF10 40 >12
Discussion:
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Results  of  floating properties  (Table  11)  study reveal  that  all  batches  had good
floating capability. This might be due to the presence of gas generating agent, i.e., sodium
bicarbonate.  Incorporation of  sodium bicarbonate  helps  to  improve floating property by
reacting with gastric fluid, when dosage form comes in contact and produce carbon dioxide
gas which entrapped inside the hydrophilic matrices leads to increase in volume of dosage
form resulting in lowering of density and dosage form starts to float. It was also observed
that as the total concentration of the polymers increases in final formulation, floating lag
time  increases.  The  floating  lag  time  results  were  in  the  range  of  32  Sec  to 431 Sec.
Formulations  from RF1  to  RF3  which  are  formulated  by  using  HPMC  (K4M,  K15M,
K100M) showed satisfactory total floating time. Formulations from RF4 to RF6 which are
formulated  by  the  combination  of  HPMC  and  Carbopol  934P showed  decreased  total
floating time which may be due to high affinity of Carbopol towards water, which promotes
water penetration into tablet matrices, leading to increased density. Formulations from RF7
to RF9 showed increased total  floating time which may be due to the good natural  gel
strength of Chitosan.
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5.4.3. Water Uptake Studies
Table No. 12: Study of swelling characteristics of floating tablets of
Ranolazine
Batch Code
Time in hrs. (% Swelling)
2 4 6 8
RF1 75.25 102.48 67.14 59.45
RF2 117.45 176.37 184.46 107.24
RF3 68.17 97.34 61.48 53.75
RF4 87.19 119.72 78.49 72.19
RF5 127.35 194.62 181.15 113.45
RF6 82.15 113.75 70.17 65.73
RF7 66.65 93.41 55.48 47.84
RF8 105.24 169.82 161.75 94.19
RF9 58.19 89.73 51.79 42.65
RF10 54.97 82.43 47.19 40.64
Discussion: 
Water uptake (swelling) study Table No. 12 cleared that order of swelling observed
in these polymers could indicate the rates at which the preparations are able to absorb water
and swell. Maximum liquid uptake and swelling of polymers were achieved after 4-6 hrs.
The swelling index was calculated with respect to time. As the time increases, the swelling
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index was increased, because weight gain by the tablet was increased proportionally with
rate of hydration. Later on, it decreased gradually due to dissolution of outermost gelled
layer of tablet into dissolution medium. A direct relationship was observed between swelling
index and nature of polymer.
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Results and Discussion
Graph No. 10: In-Vitro Dissolution Profile of F1-F6
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Graph No. 11:  In-Vitro Dissolution Profile of F7-F10
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Results and Discussion
Discussion: 
Table  13  indicates  the  dissolution  data  of  various  batches  of  floating
tablets.  The  percentage  drug release  from batch  RF1 to  RF10 vary from 77.87 to
98.37%. For the formulation batch from RF1 to RF3, TFT was sufficient but showed
relatively less drug release as higher level of HPMC K4M, K15M, and K100M (300
mg each) were used in these formulations. The formulation batch from RF4 to RF6
showed decreased TFT and drug release was more retarded as combination of HPMC
and Carbopol 934P were used in these formulations. But the formulation batch from
RF7  to  RF9,  showed  satisfactory  results  both  in  case  of  Total  floating  time  and
percentage  drug  release.  The  formulation  RF10  which  contain  Chitosan  (300  mg)
showed drug release  to  the  extent  of  90.06 % within 10 hours.  But  the optimized
formulation RF8 (combination of HPMC K15M + Chitosan) showed satisfactory drug
release (98.37%) during the final period of study.
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5.5 Study of drug release kinetics: 
Table No. 14: Dissolution Kinetics of Ranolazine Floating Tablets
Code
Zero order First order Higuchi Krosmeyer-peppas
R2 R2 R2 R2 N
RF7 0.997 0.980 0.861 0.989 0.771
RF8 0.990 0.992 0.826 0.975 0.806
RF9 0.996 0.989 0.866 0.985 0.724
RF10 0.991 0.932 0.869 0.983 0.780
Discussion:
 Table 14 indicates the release kinetics of floating tablets of Ranolazine.
Dissolution data of the tablet of batch RF8 were subjected to treatment with
different kinetics equations, which showed that release patterns .
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Graph No. 12: Zero Order Plot
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Graph No. 12: First Order Plot
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Graph No. 13: Higuchi ‘ s Plot
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Graph No: 14 Peppas Koresmeyer‘s plot
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Discussion:
Regression co-efficient value (R2) and n values for all formulation were shown in
table 14. The release profile of the optimized formula RF8 fitted best to Korsmeyer-
Peppas model with R2 value of 0.975. As the n value for the Korsmeyer-Peppas
model was found to be less than 0.89, it follows case-2 transport.
5.6 Determination of stability study of product: 
Table 15. Stability studies of Ranolazine floating tablets.
Parameters
After 15
days
After 30
days
After 45
days
Physical appearance No change No change No change 
Weight variation (mg)  850±1.6 850±2.70 849±1.30 
Thickness (mm)  4.19±1.87 4.21±2.86 4.23±3.98 
Hardness (kg/cm2)  7.24±0.23 7.20±0.64 7.20±0.99 
Friability (%)  0.56±0.05 0.57±0.08 0.57±0.06 
Drug content (mg/Tab)  98.34±0.34 98.21±0.29 98.01±0.87 
Buoyancy lag time (Sec) 32±1.60 33±2.8 33±3.10 
Duration of Buoyancy 
(Hours)
 >12 >12 >12 
Discussion:
 According to ICH guidelines, 45 days stability study at 40C ±20C, 270C
±20C and 450C ±20C for 45 days at RH 75±5% of optimized formulation (RF8) was
carried out. It showed negligible change over time for parameters like appearance,
drug content, dissolution and assay etc., No significant difference in the drug content
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between initial and formulations stored at 40C ±20C, 270C ±20C and 450C ±20C for
45 days at RH 75±5% for 45 days.
5.7 Fig 3. In-vivo confirmation of buoyancy by using radiographic studies:
Radiographic images showing the presence of floating tablet in the stomach at different time
intervals. Images were taken after: A) Without tablet, B) 30 Mins, C) 60 Mins, D) 120 Mins,
E) 180 Mins and F) 300 Mins of tablet administration.
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Discussion:
In-vivo studies were conducted on albino rabbits to find out the gastric residence
time of the optimized formulation (RF8). The studies were based on       X-Ray radiography.
Images were taken at different time intervals to find the location of the tablet  shown in
figure 3. The tablet was found to be floating on the gastric content for about 300±10 mins.
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5.4.4. In-Vitro Dissolution Study
Table No. 13: In-Vitro Dissolution Data of Ranolazine Floating Tablet
S.NO
TIME
RF1 RF2 RF3 RF4 RF5 RF6 RF7 RF8 RF9 RF10
(hr)
1 1 7.19 6.4 9.1 6.35 5.57 7.15 14.57 12.44 16.85 15.32
2 2 12.64 10.08 13.61 10.79 8.29 12.31 22.47 19.28 24.66 23.19
3 4 28.52 23.16 29.2 25.76 21.44 26.96 35.74 30.85 37.45 34.32
4 6 42.17 37.47 42.67 38.78 33.96 40.23 49.42 44.17 52.56 54.81
5 8 57.65 48.67 59.43 54.05 43.76 56.86 65.57 62.98 68.43 74.18
6 10 68.31 56.54 69.54 62.26 52.38 64.93 84.11 78.43 87.86 90.06
7 12 84.58 81.29 87.42 77.87 75.19 79.58 96.44 98.37 95.21 94.19
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Graph No. 10: In-Vitro Dissolution Profile of F1-F6
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Graph No. 11:  In-Vitro Dissolution Profile of F7-F10
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Discussion: 
Table  13  indicates  the  dissolution  data  of  various  batches  of  floating
tablets.  The  percentage  drug release  from batch  RF1 to  RF10 vary from 77.87 to
98.37%. For the formulation batch from RF1 to RF3, TFT was sufficient but showed
relatively less drug release as higher level of HPMC K4M, K15M, and K100M (300
mg each) were used in these formulations. The formulation batch from RF4 to RF6
showed decreased TFT and drug release was more retarded as combination of HPMC
and Carbopol 934P were used in these formulations. But the formulation batch from
RF7  to  RF9,  showed  satisfactory  results  both  in  case  of  Total  floating  time  and
percentage  drug  release.  The  formulation  RF10  which  contain  Chitosan  (300  mg)
showed drug release  to  the  extent  of  90.06 % within 10 hours.  But  the optimized
formulation RF8 (combination of HPMC K15M + Chitosan) showed satisfactory drug
release (98.37%) during the final period of study.
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5.5 Study of drug release kinetics: 
Table No. 14: Dissolution Kinetics of Ranolazine Floating Tablets
Code
Zero order First order Higuchi Krosmeyer-peppas
R2 R2 R2 R2 N
RF7 0.997 0.980 0.861 0.989 0.771
RF8 0.990 0.992 0.826 0.975 0.806
RF9 0.996 0.989 0.866 0.985 0.724
RF10 0.991 0.932 0.869 0.983 0.780
Discussion:
 Table 14 indicates the release kinetics of floating tablets of Ranolazine. Dissolution
data  of  the  tablet  of  batch  RF8 were  subjected  to  treatment  with  different  kinetics
equations, which showed that release patterns .
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Graph No. 12: Zero Order Plot
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Graph No. 12: First Order Plot
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Graph No. 13: Higuchi ‘ s Plot
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Graph No: 14 Peppas Koresmeyer‘s plot
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Discussion:
Regression co-efficient value (R2) and n values for all formulation were shown in table 14. The
release profile of the optimized formula RF8 fitted best to Korsmeyer-Peppas model with R2
value of 0.975. As the n value for the Korsmeyer-Peppas model was found to be less than 0.89, it
follows case-2 transport.
5.6 Determination of stability study of product: 
Table 15. Stability studies of Ranolazine floating tablets.
Parameters After 15 days After 30 days After 45 days
Physical appearance No change No change No change 
Weight variation (mg)  850±1.6 850±2.70 849±1.30 
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Thickness (mm)  4.19±1.87 4.21±2.86 4.23±3.98 
Hardness (kg/cm2)  7.24±0.23 7.20±0.64 7.20±0.99 
Friability (%)  0.56±0.05 0.57±0.08 0.57±0.06 
Drug content (mg/Tab)  98.34±0.34 98.21±0.29 98.01±0.87 
Buoyancy lag time (Sec) 32±1.60 33±2.8 33±3.10 
Duration of Buoyancy (Hours)  >12 >12 >12 
Discussion:
 According to ICH guidelines, 45 days stability study at 40C ±20C, 270C ±20C and
450C ±20C for 45 days at RH 75±5% of optimized formulation (RF8) was carried out. It showed
negligible change over time for parameters like appearance, drug content, dissolution and assay
etc., No significant difference in the drug content between initial and formulations stored at 40C
±20C, 270C ±20C and 450C ±20C for 45 days at RH 75±5% for 45 days.
5.7 Fig 3. In-vivo confirmation of buoyancy by using radiographic studies:
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Radiographic images showing the presence of floating tablet in the stomach at different time intervals. 
Images were taken after: A) Without tablet, B) 30 Mins, C) 60 Mins, D) 120 Mins, E) 180 Mins and F) 
300 Mins of tablet administration.
Discussion:
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In-vivo studies were conducted on albino rabbits to find out the gastric residence time of the optimized 
formulation (RF8). The studies were based on       X-Ray radiography. Images were taken at different time
intervals to find the location of the tablet shown in figure 3. The tablet was found to be floating on the 
gastric content for about 300±10 mins.
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SUMMARY
        Ranolazine is used for the treatment of Angina pectoris, which has a short
elimination half-life of 1.4-1.9 hours. Its dose is 500 to 1000 mg daily in divided
doses. Because of frequent administration and short elimination half-life, Ranolazine
is considered as an ideal drug for designing a sustained release formulation. 
 Floating tablets were developed to prolong the gastric residence time and
increase drug bioavailability.
 Ranolazine was chosen as a model drug because it is poorly absorbed from
the lower gastrointestinal tract.
   FTIR studies concluded that there were no interaction in drug and polymer.
 Tablets were prepared by direct compression technique, using polymers such
as  HPMC  different  grades,  Carbopol  934P,  Chitosan  alone  and  in
combination, and other standard excipients. According to this formulation
codes  RF1,  RF2,  RF3,  RF4,  RF5,  RF6,  RF7,  RF8,  RF9 and  RF10  were
prepared.
 Tablets  were  evaluated  for  physical  properties,  viz.  hardness,  friability,
weight variation, in vitro Buoyancy and swelling studies etc. Further, tablets
were evaluated for  in vitro release characteristics for 12 hrs. Drug release
kinetics  was  studied  for  zero  order,  first  order,  Higuchi  order  and
Korsmeyer-Peppas order.
 In vivo confirmation of Buoyancy was performed.
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CONCLUSION
      From the above study it can be concluded that promising controlled release
by  gastro  retentive  floating  tablets  of  Ranolazine  was  developed  using  a
combination of HPMC K15M and Chitosan. 
 The floating tablet of Ranolazine was capable of maintaining plasma drug
concentration through 12 hrs.
 The  release  rate  of  the  drug  from  the  floating  tablets  was  significantly
influenced by the proportion as well as viscosity of the polymer used. 
 The formulation RF8 was selected as an optimized formulation because it
gave the best result in terms of the required  in-vitro buoyancy study, good
floating integrity and drug release in sustained release manner. 
 The  release  profile  of  the  optimized  formula,  fitted  best  to  Korsmeyer-
Peppas model with R2 value of 0.975. 
 As the n value for the Korsmeyer-Peppas model was found to be less than
0.89, it follows case-2 transport. 
 In-vivo radiographic studies revealed that the tablets remain in the stomach
for 300±10 mins which indicates the increase in the gastric residence time. 
 Short-term  stability  studies  indicated  no  appreciable  changes  in  the  drug
content and In-vitro drug release rates of formulation RF8.
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